An Open-Label Extension Study of Patients Previously Enrolled in Study CIN-107-124 to Evaluate the Long-Term Safety and Effectiveness of CIN-107
Phase: PHASE2
Conditions: Hypertension
Sponsor: AstraZeneca

 
 
CLINICAL STUDY PROTOCOL 
 
An Open-Label Extension Study of Patients Previously Enrolled in 
Study CIN-107-124 to Evaluate the Long-Term Safety and 
Effectiveness of CIN-107  
 
Investigational Product: CIN-107 (Generic Name: Baxdrostat) 
Protocol D Code: D6971C00001 
Study Name: HALO-OLE CIN-107-130 
 
 
Sponsor: 
AstraZeneca AB 
Västra Mälarehamnen 
SE-151 85 Södertälje, Sweden 
 
 
 
Version Number: 2.0 
Date: 31 March 2023 
 
 
 
Confidentiality Statement 
The information in this document is confidential and is not to be disclosed without the written 
consent of AstraZeneca AB. (hereinafter AstraZeneca) except to the extent that disclosure would 
be required by law and for the purpose of evaluating and/or conducting a clinical study for 
AstraZeneca. You are allowed to disclose the contents of this document only to your Institutional 
Review Board or Independent Ethics Committee and study personnel directly involved with 
conducting this Protocol. Persons to whom the information is disclosed must be informed that 
the information is confidential and proprietary to AstraZeneca and that it may not be further 
disclosed to third parties. 

AstraZeneca  
Clinical Study Protocol D6971C00001
Confidential & Proprietary 
Page 2 of 66 
Version 2.0, 31 March 2023 
SIGNATURE PAGE 
STUDY TITLE: An Open-Label Extension Study of Patients Previously Enrolled in 
Study CIN-107-124 to Evaluate the Long-Term Safety and Effectiveness of CIN-107 
 
I, the undersigned, have read this Protocol and agree that it contains all necessary information 
required to conduct the study. 
Signature 
 
 
 
 
 
 
 
Date 
 
 
 

AstraZeneca  
Clinical Study Protocol D6971C00001
Confidential & Proprietary 
Page 3 of 66 
Version 2.0, 31 March 2023 
INVESTIGATOR AGREEMENT 
By signing below I agree that: 
I have read this Protocol. I approve this document and I agree that it contains all necessary details 
for carrying out the study as described. I will conduct this study in accordance with the design and 
specific provision of this Protocol and will make a reasonable effort to complete the study within 
the time designated. I will provide copies of this Protocol and access to all information furnished 
by AstraZeneca, to study personnel under my supervision. I will discuss this material with them to 
ensure they are fully informed about the study product and study procedures. I will let them know 
that this information is confidential and proprietary to AstraZeneca and that it may not be further 
disclosed to third parties. I understand that the study may be terminated or enrollment suspended 
at any time by AstraZeneca, with or without cause, or by me if it becomes necessary to protect the 
best interests of the study patients. 
I agree to conduct this study in full accordance with Food and Drug Administration Regulations, 
Institutional Review Board/Ethic Committee Regulations and International Council for 
Harmonisation Guidelines for Good Clinical Practices. 
 
 
 
 
 
 
______________________________________________  
____________________ 
 
 
 
 
 
 
Date 
 
 
 
______________________________________________ 
 
 

AstraZeneca  
Clinical Study Protocol D6971C00001
Confidential & Proprietary 
Page 4 of 66 
Version 2.0, 31 March 2023 
SYNOPSIS 
TITLE: An Open-Label Extension Study of Patients Previously Enrolled in Study CIN-107-124 
to Evaluate the Long-Term Safety and Effectiveness of CIN-107 
PROTOCOL D Code: D6971C00001 
Protocol Name: HALO-OLE CIN-107-130 
INVESTIGATIONAL PRODUCT: CIN-107 
PHASE: 2 
INDICATION: Reduction of systolic blood pressure (SBP) in patients with hypertension (HTN)
OBJECTIVES: 
The primary objective is to evaluate the long-term safety and tolerability of CIN-107 over an 
extended treatment period of up to 52 weeks.  
The safety and tolerability objectives are the following:  
 To evaluate treatment-emergent adverse events (TEAEs); 
 To evaluate treatment-emergent serious adverse events (SAEs); 
 To evaluate TEAEs of special interest; 
 To evaluate TEAEs leading to premature discontinuation of study drug; 
 To evaluate treatment-emergent marked laboratory abnormalities; 
 To evaluate the change on standing SBP and diastolic blood pressure (DBP), measured 
pre-dose at the clinical site, from baseline (Visit 1) of Study CIN-107-130 to End of Treatment
(EOT);  
 To evaluate vital signs, standing blood pressure (BP) and heart rate, physical examinations, 
electrocardiograms (ECGs), body weight, and clinical laboratory evaluations, including 
standard safety chemistry panel, hematology, coagulation, and urinalysis; 
 To determine the extent of electrolyte imbalance in the study population; 
 To determine the percentage of patients requiring down-titration of CIN-107 from the maximal 
dose strength of 2 mg to a lower dose strength of 1 mg or 0.5 mg;  
 To determine the percentage of patients resuming a single background antihypertensive agent 
at 3, 6, 9, and 12 months; and 
 To determine the percentage of patients requiring rescue medication (with/without a single 
background antihypertensive agent) during study participation. 

AstraZeneca  
Clinical Study Protocol D6971C00001
Confidential & Proprietary 
Page 5 of 66 
Version 2.0, 31 March 2023 
The effectiveness objectives are to evaluate the following relative to baseline (Visit 1) in 
Study CIN-107-130 over 52 weeks: 
 The mean SBP change; 
 The mean DBP change;  
 The percentage of patients achieving a seated SBP <130 mmHg;  
 The percentage of non-responders in Study CIN-107-124 achieving a seated SBP response 
<130 mmHg with CIN-107 (with/without a single background antihypertensive agent and/or 
rescue medication), irrespective of Study CIN-107-124 dose strength; and 
 The percentage of responders in Study CIN-107-124 maintaining a seated SBP response 
<130 mmHg with CIN-107 (with/without a single background antihypertensive agent and/or 
rescue medication), irrespective of Study CIN-107-124 dose strength. 
The pharmacokinetic (PK)-pharmacodynamic (PD) objective is to evaluate exposure-response 
relationships of CIN-107 using measures of safety, PD, and/or effectiveness. 
POPULATION: 
Patients who participated in and completed Part 1 or Part 2 of Study CIN-107-124 and did not 
discontinue the study drug for any reason, including an adverse event (AE), will be eligible for 
this study. 
Inclusion Criteria 
Patients who meet all of the following criteria will be eligible to participate: 
1. Have completed Part 1 or Part 2 of Study CIN-107-124; 
Note: Patients who have completed Part 1 but were not eligible for Part 2 of 
Study CIN-107-124 may consent to Study CIN-107-130. 
2. Have had acceptable safety and tolerability during Study CIN-107-124 as determined by the 
Investigator or Medical Monitor;  
3. Have demonstrated 70% and 120% adherence to their single background antihypertensive 
agent and the CIN-107 placebo during Study CIN-107-124; 
4. Agree to comply with the contraception and reproduction restrictions of the study as follows:
o Male patients must agree to abstain from sperm donation from Day 1 through 90 days after 
the final dose of study drug; 
o Female patients of childbearing potential (ie, ovulating, pre-menopausal, and not 
surgically sterile) must have a documented negative serum pregnancy test at enrollment
(Visit 1); and 

AstraZeneca  
Clinical Study Protocol D6971C00001
Confidential & Proprietary 
Page 6 of 66 
Version 2.0, 31 March 2023 
o
Female patients of childbearing potential must use a highly effective method of 
contraception (ie, <1% failure rate) from Day 1 through 30 days after the last 
administration of study drug. 
Note: Acceptable methods of contraception for female patients enrolled in the study 
include the following:  
 Surgical sterilization (eg, hysterectomy, bilateral oophorectomy, bilateral tubal 
ligation); 
 Intrauterine device for at least 12 weeks before enrollment (Visit 1); 
 Hormonal contraception (oral, implant, injection, ring, or patch) for at least 12 weeks 
before enrollment (Visit 1); or  
 Diaphragm used in combination with spermicide. 
Note: Postmenopausal female patients, who were either >60 years or had follicle-stimulating 
hormone (FSH) in the post-menopausal range during screening for Study CIN-107-124, must 
continue to have no menstrual bleeding for at least 1 year prior to enrollment (Visit 1), and 
therefore do not require FSH testing. 
5. Are able and willing to give informed consent for participation in the clinical study. 
Exclusion Criteria 
Patients who meet any of the following criteria will be excluded from participation in the study: 
1. Have met Protocol-defined stopping criteria, were withdrawn from the study, discontinued 
CIN-107 at the time of Visits 6 or 9, or were not compliant with the Protocol during 
Study CIN-107-124;  
2. Have received treatment with any investigational agent for disease intervention (ie, other than 
study drug) during Study CIN-107-124, or since the last administration of study drug in 
Study CIN-107-124, or plans to participate in another clinical study within 30 days of 
discontinuation of study drug;  
3. Have had any new, significant, or uncontrolled comorbidity since initially enrolling in 
Study CIN-107-124 that would increase the risk of the patient in Study CIN-107-130, as 
determined by the Investigator;  
4. Have had a mean seated SBP 170 mmHg or DBP 105 mmHg at the end of Part 1 or Part 2 
of Study CIN-107-124; 
Note: Mean seated BP is defined as the average of 3 seated BP measurements.  
5. Have an upper arm circumference that does not meet the cuff measurement criteria for the 
selected BP machine at Visit 1 of Study CIN-107-130; 
6. Have any uncontrolled or clinically significant laboratory abnormality that would affect safety, 
, as determined by the 
Investigator; 
 

AstraZeneca  
Clinical Study Protocol D6971C00001
Confidential & Proprietary 
Page 7 of 66 
Version 2.0, 31 March 2023 
7. Have experienced a de novo or reactivated serious viral infection such as hepatitis B, 
hepatitis C, or HIV during Study CIN-107-124;  
Note: Patients who experienced a viral infection during Study CIN-107-124 (ie, seasonal flu, 
Coronavirus Disease 2019, etc) are not excluded if recovered and asymptomatic within 
4 weeks of Visit 1 in Study CIN-107-130. 
8. Have had any major episode of infection requiring hospitalization or treatment with 
intravenous antibiotics during Study CIN-107-124; 
9. Have developed a malignancy (with the exception of non-serious local and resectable basal or 
squamous cell carcinoma of the skin) during Study CIN-107-124; 
10. Have anticipated initiation of erythropoietin-stimulating agents and/or planned transfusion 
within 2 months after enrollment (Visit 1); 
11. Are expected to receive or are receiving any of the exclusionary drugs (strong cytochrome 
P450 3A inducers); 
12. Have known secondary causes of HTN (eg, renal artery stenosis, uncontrolled or untreated 
hyperthyroidism, 
uncontrolled 
or 
untreated 
hypothyroidism, 
hyperparathyroidism, 
apnea; 
Note: Patients with primary aldosteronism CAN BE considered for enrollment unless an 
adrenalectomy is expected before the end of their participation in the study. 
13. Have been diagnosed with New York Heart Association stage III or IV chronic heart failure 
during Study CIN-107-124; 
14. Have had a stroke, transient ischemic attack, hypertensive encephalopathy, acute coronary 
syndrome, or hospitalization for heart failure during Study CIN-107-124; 
15. Have a known current severe left ventricular outflow obstruction, such as obstructive 
hypertrophic cardiomyopathy and/or severe aortic valvular disease diagnosed from a prior 
echocardiogram; 
16. Have a planned coronary revascularization (percutaneous coronary intervention [PCI] or 
coronary artery bypass graft [CABG]) or any major surgical procedure; 
17. Have had a CABG or other major cardiac surgery (eg, valve replacement), peripheral arterial 
bypass surgery, or PCI during Study CIN-107-124; 
18. Have a planned dialysis or kidney transplant during the course of this study; 
19. Have a known hypersensitivity to CIN-107 or drugs of the same class, or any of its excipients;
20. Have any clinically relevant medical or surgical conditions (including unstable conditions 
and/or treatment with systemic immunosuppressants including corticosteroids) that, in the 
opinion of the Investigator, would put the patient at risk by participating in the study;  

AstraZeneca  
Clinical Study Protocol D6971C00001
Confidential & Proprietary 
Page 8 of 66 
Version 2.0, 31 March 2023 
21. Are pregnant, breastfeeding, or planning to become pregnant during the study; or
22. Are considered to be unsuitable for any other reason that may either place the patient at 
increased risk during participation or interfere with the interpretation of the study outcomes 
by the Investigator, after reviewing medical and psychiatric history, physical examination, and 
laboratory evaluation. 
STUDY DESIGN AND DURATION: 
This is a Phase 2, multicenter, open-label extension (OLE) study to evaluate the long-term safety, 
tolerability, and effectiveness of CIN-107 for up to 52 weeks in patients with HTN who have 
completed Part 1 or Part 2 of Study CIN-107-124. The study will be conducted at clinical sites
that have participated in the double-blind, Phase 2 Study CIN-107-124. Patients will be assigned 
the same patient number they have had in Study CIN-107-124.  
Written informed consent must be obtained before any Protocol-specific procedures are performed 
in this study (Study CIN-107-130). Eligible patients from Study CIN-107-124 who elect to 
participate in the OLE will be enrolled directly following the EOT assessments at the end of Part 1 
or Part 2 of Study CIN-107-124 (ie, they will not undergo the safety follow-up in 
Study CIN-107-124). The EOT assessments at the end of Part 1 or Part 2 of Study CIN-107-124 
will serve as the Day 1 pre-dose assessments for those enrolling in Study CIN-107-130. 
Enrolled patients will continue treatment with 2 mg CIN-107 tablets. The guiding principle for 
medical decision making with regard to BP management in the OLE study is to try to maintain 
patients on the highest dose of CIN-107 that is safe and medically reasonable. Investigators will 
be allowed to determine whether the patient should start the OLE study with an additional single 
background antihypertensive (non-CIN-107) agent based on the patient s BP control in 
Study CIN-107-124 (ie, whether the patient in addition to the CIN-107 study drug would start the 
OLE study with an additional single background antihypertensive agent from another or same 
class as during Part 1 of Study CIN-107-124).  
The single background antihypertensive agent chosen at Visits 1 or 2 should remain stable until 
Visit 3 of the OLE study, after which the Investigator is permitted to use his/her medical judgment 
to up/down titrate or discontinue the background antihypertensive (non-CIN-107) agent.  
Rescue medication use is permitted and recommended if the SBP shows an acute and sustained 
increase of 30 mmHg (or greater) from Visit 1 and/or is 
170 mmHg and/or the DBP is 
105 mmHg in office measurement. Investigators should use their best clinical judgment when 
determining the need for rescue medications and are encouraged to discuss selection of rescue 
medication with the study Medical Monitors. 
The Investigator is to document the clinical rationale for adding, changing dose, or discontinuing
either the single background antihypertensive agent or rescue medication. The range of 
antihypertensive classes that may be used (listed in Appendix E) during this study is left to the 
-sparing diuretics and mineralocorticoid receptor 
antagonists are not allowed. 
To manage persistent or symptomatic hypotension, the Investigator should first reduce or 
discontinue any rescue medication, and then reduce or discontinue use of the single background
antihypertensive (non-CIN-107) agent if medically sound. If the symptoms continue, the dose 
strength of CIN-107 may be down-titrated from 2 mg to 1 mg. The CIN-107 dose may be further 

AstraZeneca  
Clinical Study Protocol D6971C00001
Confidential & Proprietary 
Page 9 of 66 
Version 2.0, 31 March 2023 
down-titrated to 0.5 mg if the SBP remains 100 mmHg for 3 consecutive days or if symptoms 
persist. CIN-107 may be temporarily discontinued if the SBP remains <90 mmHg for 
3 consecutive days or if symptoms persist. Study drug dosing may be resumed or up-titrated after 
reassessments.  
Patients will complete approximately 8 study visits during the OLE study, including enrollment
(Visit 1) and follow-up (Visit 8) visits. During the treatment period, patients will return to the 
clinical site for visits. Unscheduled visits may be scheduled at any time during the study period 
based on the 
 Every effort should be made to secure the continued 
participation of patients. 
The safety and tolerability of CIN-107 will be assessed from the day of the first dose of study drug 
in Study CIN-107-130 until the end of the follow-up visit. Patients will be followed for 
effectiveness and adherence throughout the treatment period. PD variables analyzed during the 
study may include, but are not limited to, measures of aldosterone and its precursors, cortisol and 
its precursor, and plasma renin activity (PRA), and calculation of aldosterone/PRA ratio. PK 
variables analyzed during the study will include plasma concentrations of CIN-107 and any 
measured metabolite(s). 
Clinical sites will provide patients with a 24-hour urine collection kit at Visit 6. Patients will be 
instructed to start the collection up to 3 days prior to Visit 7, refrigerate the collected sample, and 
bring the entire sample to the clinical site at Visit 7. A 24-hour urine collection will commence 
after the first morning void on the first day and will include the first morning void on the second 
day for a total duration of 24 (±2) hours. Patients must be instructed to keep the sample refrigerated 
at all times except during their transit to the clinical site. A 24-hour urine collection may be 
repeated if the Investigator suspects that the sampling is insufficient and the patient is within the 
visit window. Clinical sites will aliquot urine into a transfer tube and send it to the Central 
Laboratory. 
On clinical site visit days, patients will self-administer the morning dose of any other concomitant 
medications (if applicable) at home. CIN-107 should be withheld as it will be self-administered at 
the clinical site and witnessed by site staff, after completion of pre-dose evaluations and laboratory 
sampling. Between clinical site visits, patients will continue to self-administer study drug once 
daily (QD) by mouth at approximately the same time each morning. Patients will be instructed to 
bring their antihypertensive medication(s) and study drug to all clinical site visits for pill counts. 
Patients should not exercise, smoke, or consume caffeinated beverages or food for at least 2 hours 
prior to each clinical site visit. All clinical site visits should occur between 6:00 a.m. and 
11:00 a.m. 
DOSAGE FORMS AND ROUTE OF ADMINISTRATION: 
CIN-107 tablets will be provided in 0.5, 1, and 2 mg dose strengths. The tablets will be packaged 
in blister packs to achieve the doses required for the study. 
Eligible patients from Study CIN-107-124 who elect to participate in this study will continue 
treatment with 2 mg CIN-107 tablets QD after enrollment, starting at Visit 1 and concluding at 
EOT (Visit 7). 

AstraZeneca  
Clinical Study Protocol D6971C00001
Confidential & Proprietary 
Page 10 of 66 
Version 2.0, 31 March 2023 
STUDY WITHDRAWAL AND STUDY DRUG DISCONTINUATION CRITERIA: 
A patient will be withdrawn from this clinical study for any of the following reasons: 
 The patient withdraws consent or requests discontinuation from the study for any reason; or 
 The study is terminated by the Sponsor or the regulatory authority. 
The study drug will be discontinued for any of the following reasons: 
 Occurrence of any medical condition or circumstance, SAE, clinically significant AE, severe 
laboratory abnormality, or intercurrent illness which exposes the patient to substantial risk, 
does not allow the patient to adhere to the requirements of the Protocol, and/or indicates to the 
Investigator that continued participation is not in the best interest of the patient; 
 Requirement of excluded concomitant medication and/or procedure; or 
 The patient becomes pregnant. 
If a patient withdraws prematurely from the study due to the above criteria or any other reason, 
he/she will be requested to undergo the Early Termination (ET) procedures, and site staff should 
make every effort to complete the full panel of assessments scheduled for EOT (Visit 7) at ET.
The reason for patient withdrawal must be documented in the electronic case report form. Patients 
who prematurely discontinue study drug treatment should complete the remaining study visits for 
safety monitoring despite discontinuation of study drug. Withdrawn patients will not be replaced.
SAFETY AND TOLERABILITY ENDPOINTS: 
The safety and tolerability of CIN-107 will be assessed from the day of the first dose of study drug 
in Study CIN-107-130 until the end of the follow-up visit. The safety and tolerability endpoints 
will include the following: 
 TEAEs; 
 Treatment-emergent SAEs; 
 TEAEs of special interest; 
 TEAEs leading to premature discontinuation of study drug; 
 Treatment-emergent marked laboratory abnormalities;  
 Change on standing SBP and DBP, measured pre-dose at the clinical site, from baseline
(Visit 1) of Study CIN-107-130 to EOT (Visit 7); 
 Vital signs, standing BP and heart rate, physical examinations, ECGs, body weight, and 
clinical laboratory evaluations, including standard safety chemistry panel, hematology, 
coagulation, and urinalysis; 
 The percentage of patients with electrolyte imbalance; 
 The percentage of laboratory results with electrolyte imbalance;  
 The percentage of patients requiring down-titration of CIN-107 from the maximal dose 
strength of 2 mg to a lower dose strength of 1 mg or 0.5 mg; 

AstraZeneca  
Clinical Study Protocol D6971C00001
Confidential & Proprietary 
Page 11 of 66 
Version 2.0, 31 March 2023 
 The percentage of patients resuming a single background antihypertensive agent at 3, 6, 9, and 
12 months; and 
 The percentage of patients requiring rescue medication (with/without a single background 
antihypertensive agent) during study participation. 
EFFECTIVENESS ENDPOINTS:  
The effectiveness endpoints include the following: 
 Change from baseline in mean seated SBP with CIN-107 over the 52-week treatment period. 
Baseline mean seated SBP is the value at Visit 1 of Study CIN-107-130; 
 Change from baseline in mean seated DBP with CIN-107 over the 52-week treatment period. 
Baseline mean seated DBP is the value at Visit 1 of Study CIN-107-130;  
 The percentage of patients achieving a seated SBP response <130 mmHg with CIN-107 
monotherapy without a single background antihypertensive agent over the 52-week treatment 
period; 
 The percentage of non-responders in Study CIN-107-124 achieving a seated SBP response 
<130 mmHg with CIN-107 (with/without a single background antihypertensive agent and/or 
rescue medication), irrespective of Study CIN-107-124 dose strength; 
 The percentage of responders in Study CIN-107-124 maintaining a seated SBP response 
<130 mmHg with CIN-107 (with/without a single background antihypertensive agent and/or 
rescue medication), irrespective of Study CIN-107-124 dose strength; 
 PD variables analyzed during the study, including measures of aldosterone and its precursors, 
cortisol and its precursor, and PRA, and calculated aldosterone/PRA ratio; and 
 PK variables analyzed during the study, including plasma concentrations of CIN-107 and any 
measured metabolite(s). 
STATISTICAL ANALYSES: 
Study CIN-107-130 is a multicenter, single arm, OLE study. The primary objective of this study 
is to assess the long-term safety and tolerability of CIN-107 in patients with HTN who have 
completed the parent Study CIN-107-124. The baseline values for safety and tolerability endpoints
and effectiveness endpoints are defined as the values at Visit 1 prior to starting the first dose in 
Study CIN-107-130.  
No formal hypothesis testing is planned. Additional details of analyses to be performed will be 
specified in the Statistical Analysis Plan. 
The Safety Population will be the primary population used for analyses. The Safety Population 
includes any patients enrolled in Study CIN-107-130 who have taken at least 1 dose of any study 
drug.  
All safety and tolerability endpoints will be summarized descriptively. The Safety Population will 
be the primary population used for analyses. 

AstraZeneca  
Clinical Study Protocol D6971C00001
Confidential & Proprietary 
Page 12 of 66 
Version 2.0, 31 March 2023 
The effectiveness endpoints are secondary endpoints of this study. The change from baseline over 
time will be analyzed. The analyses will be performed descriptively based on data in the Safety 
Population. 
Additional analyses may be conducted with data collected in the parent Study CIN-107-124 to 
assess safety, tolerability, and effectiveness of CIN-107 from the first exposure.  
No interim analysis is planned. 
SAMPLE SIZE DETERMINATION: 
The study sample size is predicated on the overall size of the parent Study CIN-107-124. It is 
estimated that about 200 patients will enroll in this study. 
SITES: Clinical sites that participated in the Phase 2 Study CIN-107-124 are eligible to 
participate. 
SPONSOR: 
AstraZeneca AB 
Västra Mälarehamnen, SE-151 85  
Södertälje, Sweden 
 

AstraZeneca  
Clinical Study Protocol D6971C00001
Confidential & Proprietary 
Page 13 of 66 
Version 2.0, 31 March 2023 
TABLE OF CONTENTS 
Signature Page ................................................................................................................................ 2 
Investigator Agreement ................................................................................................................... 3 
Synopsis .......................................................................................................................................... 4 
Table of Contents .......................................................................................................................... 13 
List of Tables ................................................................................................................................ 17 
List of Abbreviations and Definition of Terms............................................................................. 18 
1 Introduction and Background Information ............................................................................. 20 
1.1 
Overview of Non-Clinical Studies ................................................................................ 20 
1.2 
Overview of Clinical Studies With CIN-107 ................................................................ 21 
1.2.1 Clinical Studies in Healthy Patients .................................................................. 21 
1.3 
Study CIN-107-124 (HALO Study) .............................................................................. 23 
1.4 
Rationale for Conducting Study CIN-107-130 ............................................................. 24 
1.5 
Risk/Benefit ................................................................................................................... 24 
1.5.1 Potential Risks ................................................................................................... 24 
1.5.1.1 Risk of hyperkalemia and hyponatremia ............................................ 24 
1.5.1.2 Risk of hypovolemia and orthostatic hypotension .............................. 24 
1.5.1.3 Risk of adrenal effects ........................................................................ 24 
1.5.1.4 Risk of sex hormone-related adverse events ....................................... 24 
1.5.1.5 Risk of allergic reactions .................................................................... 24 
1.5.2 Potential Benefits .............................................................................................. 24 
2 Study Objectives ..................................................................................................................... 26 
2.1 
Primary Objective ......................................................................................................... 26 
2.1.1 Safety and Tolerability Objectives .................................................................... 26 
2.2 
Effectiveness Objectives ............................................................................................... 26 
2.3 
Pharmacokinetic-Pharmacodynamic Objective ............................................................ 27 
3 Study Description.................................................................................................................... 28 
3.1 
Summary of Study Design ............................................................................................ 28 
3.2 
Study Indication ............................................................................................................ 29 
4 Selection and Withdrawal of Patients ..................................................................................... 30 
4.1 
Population ...................................................................................................................... 30 

AstraZeneca  
Clinical Study Protocol D6971C00001
Confidential & Proprietary 
Page 14 of 66 
Version 2.0, 31 March 2023 
4.2 
Inclusion Criteria ........................................................................................................... 30 
4.3 
Exclusion Criteria .......................................................................................................... 31 
4.4 
Study Withdrawal and Study Drug Discontinuation Criteria ........................................ 32 
5 Study Treatments .................................................................................................................... 34 
5.1 
Treatment Groups .......................................................................................................... 34 
5.2 
Rationale for Dosing ..................................................................................................... 34 
5.3 
Blinding ......................................................................................................................... 34 
5.4 
Drug Supplies ................................................................................................................ 34 
5.4.1 Formulation and Packaging ............................................................................... 34 
5.4.2 Study Drug Preparation and Dispensing ........................................................... 34 
5.4.2.1 Background antihypertensive agent .................................................... 34 
5.4.2.2 Study drug ........................................................................................... 34 
5.4.3 Study Drug Administration ............................................................................... 35 
5.4.4 Treatment Compliance ...................................................................................... 35 
5.4.5 Storage and Accountability ............................................................................... 35 
5.5 
Prior and Concomitant Medications and/or Procedures ................................................ 36 
5.5.1 Excluded Medications and/or Procedures ......................................................... 36 
5.5.2 Restricted Medications and/or Procedures ........................................................ 36 
5.5.3 Allowed Medications and/or Procedures .......................................................... 36 
5.5.4 Dietary Guidance ............................................................................................... 37 
5.5.5 Documentation of Prior and Concomitant Medication Use .............................. 37 
6 Study Procedures .................................................................................................................... 38 
7 Effectiveness Assessments...................................................................................................... 39 
7.1 
Effectiveness Endpoints ................................................................................................ 39 
7.2 
Pharmacokinetic and Pharmacodynamic Assessment ................................................... 39 
7.2.1 Pharmacodynamic Blood Sampling .................................................................. 39 
7.2.2 Twenty-Four-Hour Urine Collection ................................................................ 39 
7.3 
Pharmacokinetic Assessments ....................................................................................... 40 
8 Safety And Tolerability Assessments ..................................................................................... 41 
8.1 
Adverse Events .............................................................................................................. 41 
8.1.1 Adverse (Drug) Reaction .................................................................................. 42 
8.1.2 Unexpected Adverse Drug Reaction ................................................................. 42 

AstraZeneca  
Clinical Study Protocol D6971C00001
Confidential & Proprietary 
Page 15 of 66 
Version 2.0, 31 March 2023 
8.1.3 Assessment of Adverse Events by the Investigator .......................................... 42 
8.1.4 Adverse Events of Special Interest .................................................................... 43 
8.2 
Serious Adverse Events ................................................................................................. 44 
8.3 
Serious Adverse Event Reporting  Procedures for Investigators ................................ 44 
8.4 
Overdose Reporting ....................................................................................................... 45 
8.5 
Safety Surveillance and Management of Serum Potassium Levels .............................. 45 
8.6 
Pregnancy Reporting ..................................................................................................... 46 
8.7 
Expedited Reporting ...................................................................................................... 46 
8.8 
Clinical Laboratory Evaluations .................................................................................... 47 
8.9 
Vital Signs ..................................................................................................................... 47 
8.10 Electrocardiograms ........................................................................................................ 48 
8.11 Physical Examination .................................................................................................... 48 
8.12 Body Measurement ....................................................................................................... 49 
9 Statistics .................................................................................................................................. 50 
9.1 
Analysis Populations ..................................................................................................... 50 
9.2 
Statistical Methods ........................................................................................................ 50 
9.2.1 Analysis of Safety ............................................................................................. 50 
9.2.2 Analysis of Effectiveness .................................................................................. 50 
9.2.2.1 Analysis of effectiveness endpoints .................................................... 50 
9.2.2.2 Other effectiveness analyses ............................................................... 50 
9.2.3 Interim Analysis ................................................................................................ 50 
9.2.4 Sample Size Determination ............................................................................... 50 
10 Data Management and Record Keeping ................................................................................. 51 
10.1 Data Management ......................................................................................................... 51 
10.1.1 Data Handling ................................................................................................... 51 
10.1.2 Computer Systems ............................................................................................. 51 
10.1.3 Data Entry ......................................................................................................... 51 
10.1.4 Medical Information Coding ............................................................................. 51 
10.1.5 Data Validation ................................................................................................. 51 
10.2 Record Keeping ............................................................................................................. 51 
10.3 End of Study .................................................................................................................. 52 
11 Investigator Requirements and Quality Control ..................................................................... 53 

AstraZeneca  
Clinical Study Protocol D6971C00001
Confidential & Proprietary 
Page 16 of 66 
Version 2.0, 31 March 2023 
11.1 Ethical Conduct of the Study ........................................................................................ 53 
11.2 Institutional Review Board/Independent Ethics Committee ......................................... 53 
11.3 Informed Consent .......................................................................................................... 53 
11.4 Study Monitoring Requirements ................................................................................... 53 
11.5 Disclosure of Data ......................................................................................................... 54 
11.6 Retention of Records ..................................................................................................... 54 
11.7 Publication Policy ......................................................................................................... 54 
11.8 Financial Disclosure ...................................................................................................... 55 
12 Study Administrative Information .......................................................................................... 56 
12.1 Protocol Amendments ................................................................................................... 56 
12.2 Address List ................................................................................................................... 56 
12.2.1 Sponsor .............................................................................................................. 56 
12.2.2 Contract Research Organization ........................................................................ 56 
12.2.3 Serious Adverse Event Reporting ..................................................................... 56 
12.2.4 Biological Specimens ........................................................................................ 56 
12.2.5 Central Pharmacy .............................................................................................. 57 
12.2.6 Central Depot .................................................................................................... 57 
13 References ............................................................................................................................... 57 
Appendix A:  Schedule of Procedures .......................................................................................... 59 
Appendix B:  Clinical Laboratory Analytes ................................................................................. 61 
Appendix C:  Electrocardiogram Alert Criteria Guidance ........................................................... 63 
Appendix D:  Examples of Excluded Medications ....................................................................... 64 
Appendix E:  Rescue Medication Guidance ................................................................................. 65 
Appendix F:  Down-Titration of Antihypertensive Medication(s) ............................................... 66 

AstraZeneca  
Clinical Study Protocol D6971C00001
Confidential & Proprietary 
Page 17 of 66 
Version 2.0, 31 March 2023 
LIST OF TABLES 
Table 1. 
Schedule of Procedures  Open-Label Extension ....................................................... 59 
Table 2. 
Examples of Excluded Medications ............................................................................ 64 
 
 

AstraZeneca  
Clinical Study Protocol D6971C00001
Confidential & Proprietary 
Page 18 of 66 
Version 2.0, 31 March 2023 
LIST OF ABBREVIATIONS AND DEFINITION OF TERMS  
Abbreviation 
Definition 
AE 
Adverse event 
AESI 
Adverse event of special interest 
AOBPM 
Automated office blood pressure monitoring  
AUC 
Area under the concentration-time curve 
BMI 
Body mass index 
BP  
Blood pressure 
CABG 
Coronary artery bypass graft 
CFR 
Code of Federal Regulations 
Cmax 
Maximum plasma concentration 
CRA 
Clinical research associate 
CYP 
Cytochrome P450 
DBP 
Diastolic blood pressure  
ECG 
Electrocardiogram 
eCRF 
Electronic case report form 
EDC 
Electronic data capture 
eGFR 
Estimated glomerular filtration rate 
EIU 
Exposure In Utero 
EOT 
End of Treatment 
ET 
Early Termination  
FDA 
Food and Drug Administration 
FSH 
Follicle-stimulating hormone 
GCP 
Good Clinical Practice 
HIV 
Human immunodeficiency virus 
HTN 
Hypertension 
ICF 
Informed consent form 
ICH 
International Council for Harmonisation 
IRB 
Institutional Review Board 
MAD 
Multiple-ascending dose 
MR 
Mineralocorticoid receptor 
MRA 
Mineralocorticoid receptor antagonist 
NOAEL 
No observed adverse effect level 
OLE 
Open-label extension 
PCI 
Percutaneous coronary intervention 
PD 
Pharmacodynamic(s) 
PK 
Pharmacokinetic(s) 
PRA 
Plasma renin activity 
QD 
Once daily 

AstraZeneca  
Clinical Study Protocol D6971C00001
Confidential & Proprietary 
Page 19 of 66 
Version 2.0, 31 March 2023 
Abbreviation 
Definition 
QTc 
Heart rate-corrected QT interval 
QTcF 
Heart rate-
 
SAD 
Single-ascending dose 
SAE 
Serious adverse event 
SBP 
Systolic blood pressure  
SUSAR 
Suspected Unexpected Serious Adverse Reactions 
TEAE 
Treatment-emergent adverse event 
 

AstraZeneca  
Clinical Study Protocol D6971C00001
Confidential & Proprietary 
Page 20 of 66 
Version 2.0, 31 March 2023 
1 
INTRODUCTION AND BACKGROUND INFORMATION  
Aldosterone is a hormone that has been implicated in a variety of cardiovascular and renal diseases. 
It is the principal mineralocorticoid in humans and is synthesized in the adrenal cortex by the 
enzyme aldosterone synthase. Aldosterone is a key component of the renin angiotensin aldosterone 
system and acts as a critical regulator of fluid and electrolyte homeostasis through its agonism of 
the mineralocorticoid receptor (MR). Its effect on end organs has been shown to occur by its direct 
interaction with the MR (genomic effect) in addition to mechanisms independent of that direct 
interaction (non-genomic or non-receptor mediated effects).1,2,3 
One of the challenges that has impacted the development of aldosterone synthase inhibitors has 
been the difficulty in selectively inhibiting aldosterone synthase without affecting the synthesis of 
-hydroxylase (encoded by the 
cytochrome P450 [CYP] 11B1 gene) and shares high sequence similarity with aldosterone 
-hydroxylase leads to 
suppression of cortisol levels, compromised stress and immunologic responses, adverse effects on 
some metabolic functions, and possibly increased mortality rates.4,5,6,7 
Baxdrostat is a highly potent, selective, and competitive inhibitor of human aldosterone synthase 
(encoded by the cytochrome P450 [CYP]11B2 gene). Baxdrostat (formerly CIN-107 or 
RO6836191) was acquired from Roche Pharmaceuticals, Inc. (hereinafter Roche) by CinCor 
Pharma, Inc. (hereinafter CinCor). CinCor is a wholly owned subsidiary of the AstraZeneca group 
of companies. AstraZeneca is pursuing further clinical development of the compound. In 
preclinical in vivo studies (primarily conducted in primates), CIN-107 significantly lowered 
aldosterone without affecting cortisol levels over a wide dose range. The ability of CIN-107 to 
lower aldosterone without affecting cortisol was confirmed following administration of single oral 
doses and in the multiple-ascending dose (MAD) in healthy human patients. 
1.1 
Overview of Non-Clinical Studies 
The potential adverse effects of CIN-107 have been evaluated in standard safety pharmacology, 
genotoxicity, repeated-dose toxicity, and reproductive toxicity studies. Findings in animal models 
 
Dose- and exposure-dependent inhibition of aldosterone synthesis was confirmed in acute and 
sub chronic monkey models. In cynomolgus monkeys challenged with an injection of 
adrenocorticotropic hormone, CIN-107 blocked aldosterone synthesis without interfering with 
cortisol levels. 
Administration of CIN-107 up to 30 mg/kg/day for up to 13 weeks and up to 10 mg/kg/day for up 
to 26 weeks has been studied in Wistar Han rats. Most changes in the 13-week toxicity study were 
reversible and/or confined to the high dose level, with the exception of dose-related decreases in 
aldosterone in both sexes, which was noted at all dose levels. Based on preliminary data from the 
26-week toxicity study (Study CIN-107-RETOX007), CIN-107-related mortality occurred in 
2 female rats administered 10 mg/kg/day and who were sacrificed in moribund condition due to 
dehydration and loss of body weight. Mild, dose-responsive (females only), non-adverse increased 
serum cholesterol concentration was observed in males administered 10 mg/kg/day and females 
administered 1 mg/kg/day. Based on these data, the no observed adverse effect level (NOAEL) 
for CIN-107 in male rats is 10 mg/kg/day or a human equivalent dose of 81 mg/day. Due to the 

AstraZeneca 
Clinical Study Protocol D6971C00001
Confidential & Proprietary 
Page 21 of 66 
Version 2.0, 31 March 2023 
CIN-107-related unscheduled sacrifice of 2 females administered 10 mg/kg/day, the NOAEL for 
CIN-107 in female rats is 3 mg/kg/day which is equivalent to 24 mg/day for a 50 kg human. 
CIN-107 was administered in cynomolgus monkeys up to 6 mg/kg/day for up to 39 weeks. Based 
on preliminary results of Study CIN-107-RETOX006, no CIN-107-related clinical pathology 
changes were noted. CIN-107-related microscopic findings included adrenal hyperplasia (zona 
glomerulosa, minimal to moderate), renal juxtaglomerular hyperplasia (considered related to 
CIN-107 pharmacology), and decreased lymphocytes in multiple organs (spleen, thymus, and 
mesenteric lymph nodes) of animals administered 1 mg/kg/day. Microscopic findings showed 
evidence of reversibility. Due to the lack of impact on the health and well-being of animals, the 
NOAEL is 6 mg/kg/day for male and female monkeys or a human equivalent dose of 97 mg/day 
for a 50 kg human.  
The adrenal gland was the primary tissue affected in both rats and monkeys. CIN-107 was well 
tolerated in cynomolgus monkeys up to 7 mg/kg/day for up to 4 weeks but was not well tolerated 
at 40 mg/kg/day. A mechanistic 4-week cynomolgus monkey study demonstrated dose-related 
hypertrophy of adrenal zona glomerulosa cells with increased thickness or expansion of the zona 
glomerulosa layer, increased aldosterone synthase (CYP11B2) immunostaining, lipid vacuolation, 
apoptosis, and proliferation of zona glomerulosa cells. These pathological changes in the adrenal 
gland were ameliorated by electrolyte supplementation and angiotensin-converting enzyme 
inhibition, indicating that they were 
exaggerated pharmacological effects of and 
physiologic/adaptive responses to aldosterone inhibition. 
There was no evidence for a mutagenic, clastogenic, or aneugenic potential of CIN-107. 
In vitro cardiovascular safety was assessed in a human ether à-go-go-related gene assay. The 
concentration needed for 20% inhibition was >150-fold above the free maximum plasma 
concentration (Cmax) expected to be efficacious in man (at 10 mg once daily [QD] dose for the 
treatment of hypertension [HTN]). This indicated a very low probability of any QT liability. In a 
modified Irwin test and in a whole-body plethysmography study in male rats, single oral 
administrations of CIN-107 up to a dose of 50 mg/kg did not induce any adverse effects on the 
central nervous system or respiratory function. The NOAEL was considered to be 50 mg/kg 
CIN-107 for both studies. 
Details of the studies and results 
1.2 
Overview of Clinical Studies With CIN-107 
1.2.1 
Clinical Studies in Healthy Patients 
Four clinical pharmacology studies of CIN-107 have been conducted to date in healthy patients: a 
single-ascending dose (SAD) study, a MAD study, a study to characterize the effect of food on the 
pharmacokinetics (PK) and to bridge the PK of the solution formulation of CIN-107 to the tablet 
formulation intended for future development, and a study to assess the effect of CIN-107 on the 
PK of the multidrug and toxin extrusion substrate metformin. 
Results of the SAD study which investigated the safety, tolerability, PK, and pharmacodynamics 
(PD) of CIN-107 in healthy male volunteers demonstrated that single oral doses of CIN-107 up to 
360 mg were well tolerated. There were no deaths, serious adverse events (SAEs), or dose-limiting 
events, and the maximum tolerated dose observed was at the highest dose tested of 360 mg. 

AstraZeneca  
Clinical Study Protocol D6971C00001
Confidential & Proprietary 
Page 22 of 66 
Version 2.0, 31 March 2023 
Following oral administration, CIN-107 was rapidly absorbed with a median time to Cmax typically 
observed between 0.5 and 2 hours. A second, generally lower peak was often observed at 3 to 
4 hours post-dose. Thereafter, concentrations declined from peak in a biphasic manner with a long 
median terminal elimination half-life of approximately 25 to 31 hours. Over the anticipated 
therapeutically relevant dose range (through 10 mg), peak and overall exposures (as assessed by 
Cmax and area under the concentration-time curve [AUC]) increased in a generally 
dose-proportional manner. 
Single doses of CIN-107 reduced plasma and urine aldosterone levels by approximately 85% to 
90% in a dose-dependent manner. A maximum effect on aldosterone reduction was consistently 
achieved at a dose of 10 mg CIN-107 under the different conditions tested (Cortrosyn® challenge, 
standing, normal salt diet, and low salt diet conditions). No change in plasma cortisol levels after 
the Cortrosyn challenge was apparent across the full dose range tested (0 to 360 mg CIN-107). 
Although there was no effect on cortisol levels through 360 mg, some partial inhibition of the 
CYP11B1 enzyme at exposures well above those considered to be therapeutically relevant may 
have occurred based on observed increases in 11-deoxycortisol (at doses of 180 mg and 360 mg) 
and 11-deoxycorticosterone (at doses 90 mg). 
Single oral doses of up to 360 mg CIN-107 did not affect serum electrolyte (chloride, potassium, 
sodium, and phosphate) levels, with no difference for patients on active treatment versus those on 
placebo. Urine sodium and the sodium to potassium ratio both increased, with the sodium loss in 
urine greater than the potassium retention. No change in urine creatinine was apparent. 
Results of the MAD study indicate that multiple ascending doses of CIN-107 up to 5 mg QD for 
10 days were well tolerated by healthy patients taking low salt diet (for 2.5 and 5 mg CIN-107 
dose groups) and normal salt diet (for 0.5, 1.5, and 2.5 mg CIN-107 dose groups). Specifically, 
there were no deaths, SAEs, or treatment-emergent adverse events (TEAEs) leading to withdrawal, 
and there were no clinically significant changes in electrocardiograms (ECGs) or vital signs. PK 
data from the MAD study indicate that exposure to CIN-107 (as assessed by Cmax and AUC) is 
generally 2- to 2.5-fold higher at steady state as compared to that observed following a single dose. 
Exposures within the dose range studied increased in an approximately dose-proportional manner. 
PD data from this study confirmed the ability of CIN-107 to lower aldosterone at doses 5 mg 
without affecting levels of cortisol or its precursor 11-deoxycortisol in healthy patients. As 
expected with a reduction in aldosterone levels, there were mild, dose-dependent increases in 
plasma potassium levels and reductions in plasma sodium levels. 
The drug product used in the Phase 1 SAD and MAD studies was provided as an oral solution. A 
tablet formulation was developed and used in the Phase 1 relative bioavailability and food effect 
study (CIN-107-112). The study was conducted with a 5 mg solution (fasted) and a 5 mg tablet. 
Results of the relative bioavailability assessment indicate that exposure to CIN-107 and its primary 
metabolite following administration of the CIN-107 tablet formulation is equivalent to that 
observed following administration of the oral solution. Consumption of a high fat, high calorie 
meal had no substantial impact on the extent of absorption (as assessed by Cmax and AUC) but did 
have a small effect on the rate of absorption. Time to Cmax occurred approximately 1 hour later 
(median of 4 hours) when CIN-107 was administered with the specified meal as compared to in a 
fasted state (median of 3 hours). 
The metformin drug-drug interaction study demonstrated that systemic exposure to metformin is 
unchanged when administered with CIN-107. The safety profile of metformin was similar in the 

AstraZeneca  
Clinical Study Protocol D6971C00001
Confidential & Proprietary 
Page 23 of 66 
Version 2.0, 31 March 2023 
presence and absence of CIN-107. Specifically, there were no deaths, SAEs, or TEAEs leading to 
withdrawal and there were no clinically significant changes in ECGs or vital signs. 
The results of the renal impairment study indicated that a single 10 mg dose of CIN-107 was well 
tolerated by patients with varying degrees of renal function, ranging from normal renal function to 
end stage disease receiving hemodialysis. One patient with end stage disease experienced an 
unrelated SAE of metabolic encephalopathy and a moderate unrelated adverse event (AE) of 
tremor. One control patient experienced a mild AE of diarrhea, which was considered to be related 
to study drug by the Investigator. There were no clinically significant changes in laboratory values 
(including potassium), ECGs, or vital signs. PK data from this study demonstrated that there was 
no noteworthy increase in systemic exposure or decrease in renal clearance in individuals with 
moderate or severe renal impairment (estimated glomerular filtration rate [eGFR] 15 to 
59 mL/min) as compared to control patients (normal renal function or mild renal impairment; 
eGFR 60 mL/min). The conclusions of this study suggest that it is not necessary to dose adjust 
CIN-107 for patients with renal impairment. 
 
1.3 
Study CIN-107-124 (HALO Study) 
Study CIN-107-124, the HALO study, is the parent clinical trial of the current Study CIN-107-130. 
It is a Phase 2, randomized, multicenter study to evaluate the efficacy and safety of multiple dose 
strengths of CIN-107 for the treatment of HTN in 2 parts. Eligible patients must have uncontrolled 
HTN (mean seated systolic blood pressure [SBP] 140 mmHg [or 130 mmHg if diabetic]) despite 
being on a stable regimen of a single background antihypertensive agent at the maximal tolerated 
dose (in the opinion of the Investigator) for at least 8 weeks and must have a serum aldosterone 
7 ng/dL ( 6 ng/dL if on an angiotensin-converting enzyme inhibitor or an angiotensin receptor 
blocker) and meet all other enrollment criteria. Approximately 250 patients are to be enrolled in 
the clinical sites in the United States. A subsequent amendment of the protocol permitted patients 
being on a stable regimen of an ACEi/ARB or an ACEi/ARB plus a thiazide diuretic or an 
ACEi/ARB plus a CCB at the MTD (in the opinion of the Investigator) for at least 8 weeks to be 
enrolled.  The requirement of a baseline serum aldosterone 
7 ng/dL ( 6 ng/dL if on an 
angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker) was removed. 
Patients in the HALO study are to be randomly assigned to CIN-107 0.5 mg, 1 mg, 2 mg, or 
placebo QD for 8 weeks as the add-on therapy to their single background antihypertensive agent 
in Part 1. All responders (defined as patients achieving a mean seated SBP <130 mmHg) at the 
end of Part 1 will be qualified to participate in Part 2. Responders will receive 2 mg CIN-107 
tablets and discontinue their single background antihypertensive agent in Part 2. Non-responders 
who received any study drug except 2 mg CIN-107 in Part 1 will move into Part 2, receive the 
2 mg dose of CIN-107 for 4 weeks, and discontinue their single background antihypertensive 
agent. A non-responder who has already received the maximum dose strength (2 mg) of CIN-107 
in Part 1 will be considered withdrawn from the study. Patients who complete the study through 
12 weeks or who were considered withdrawn at the end of Part 1 may be eligible to enter the 
open-label extension (OLE) study (Study CIN-107-130). 

AstraZeneca  
Clinical Study Protocol D6971C00001
Confidential & Proprietary 
Page 24 of 66 
Version 2.0, 31 March 2023 
1.4 
Rationale for Conducting Study CIN-107-130 
The rationale for conducting an OLE study is to evaluate the long-term safety, tolerability, and 
effectiveness on blood pressure (BP) management of CIN-107 over an extended treatment period 
of up to 52 weeks. As CIN-107, if approved, will be used chronically for managing HTN, 
collection of data from patients exposed for a minimum of 1 year at dosage levels intended for 
clinical use will ensure adequate safety assessment. Patients enrolled in Study CIN-107-124, who 
have uncontrolled HTN despite being on a stable regimen of a single background antihypertensive 
agent, represent a large portion of the hypertensive population. 
1.5 
Risk/Benefit 
1.5.1 
Potential Risks 
1.5.1.1 
Risk of hyperkalemia and hyponatremia 
Aldosterone leads to increased reabsorption of sodium and water and secretion of potassium in the 
kidneys, thereby increasing blood volume and BP. Based on the preclinical observations and the 
mode of action of CIN-107, reduction of circulating aldosterone levels may lead to natriuresis and 
subsequently to increased serum potassium, decreased serum sodium, possible dehydration, and 
decreased BP. Patients with potassium and sodium levels outside of Protocol-required levels will 
be excluded from study participation and these electrolytes will be closely monitored for the entire 
study duration. 
1.5.1.2 
Risk of hypovolemia and orthostatic hypotension 
As a consequence of the urinary sodium loss described above, osmotic water loss can lead to 
hypovolemia and consequently to orthostatic hypotension with a corresponding increase in heart 
rate. These events will be followed in this study by measuring body weight and orthostatic vital 
signs (BP and heart rate). 
1.5.1.3 
Risk of adrenal effects 
While CIN-107 exhibits highly selective CYP11B2 inhibition, CYP11B1 inhibition with repeat 
dosing cannot be ruled out and may result in reduction in cortisol levels, as seen at high doses in 
preclinical studies and in clinical studies for the non-selective CYP11B1/B2 inhibitor LCI699 
(osilodrostat).8,9 
1.5.1.4 
 Risk of sex hormone-related adverse events 
Known side effects of MR antagonists (MRAs) are gynecomastia, mastodynia, and abnormal 
vaginal bleeding, and were observed more frequently with spironolactone than with eplerenone. 
Occurrence of these events will be monitored in this study. Nevertheless, a selective inhibitor of 
aldosterone synthase is not expected to interfere with sexual hormone pathways. 
1.5.1.5 
Risk of allergic reactions 
Patients with known allergies to CIN-107 or its excipients (including placebo) should not receive 
CIN-107. 
1.5.2 
Potential Benefits 
Patients enrolled in this study could benefit from the BP-lowering effect of CIN-107. 

AstraZeneca  
Clinical Study Protocol D6971C00001
Confidential & Proprietary 
Page 25 of 66 
Version 2.0, 31 March 2023 
CIN-107 is an aldosterone synthase inhibitor. Aldosterone synthase inhibition is a new therapeutic 
option for the phenomenon of aldosterone breakthrough (in which the initially reduced plasma 
aldosterone concentration returns to baseline levels over time). With aldosterone breakthrough, BP 
control may be diminished with the associated progression of end organ damage. 
Taken together, the preclinical data and existing clinical data support the activity and safety of 
CIN-107 and its continued clinical evaluation. 

AstraZeneca  
Clinical Study Protocol D6971C00001
Confidential & Proprietary 
Page 26 of 66 
Version 2.0, 31 March 2023 
2 
STUDY OBJECTIVES 
2.1 
Primary Objective 
The primary objective is to evaluate the long-term safety and tolerability of CIN-107 over an 
extended treatment period of up to 52 weeks. 
2.1.1 
Safety and Tolerability Objectives 
The safety and tolerability objectives are the following: 
 To evaluate TEAEs; 
 To evaluate treatment-emergent SAEs; 
 To evaluate TEAEs of special interest; 
 To evaluate TEAEs leading to premature discontinuation of study drug; 
 To evaluate treatment-emergent marked laboratory abnormalities; 
 To evaluate the change on standing SBP and diastolic BP (DBP), measured pre-dose at the 
clinical site, from baseline (Visit 1) of Study CIN-107-130 to End of Treatment (EOT);  
 To evaluate vital signs, standing BP and heart rate, physical examinations, ECGs, body weight, 
and clinical laboratory evaluations, including standard safety chemistry panel, hematology, 
coagulation, and urinalysis; 
 To determine the extent of electrolyte imbalance in the study population; 
 To determine the percentage of patients requiring down-titration of CIN-107 from the maximal 
dose strength of 2 mg to a lower dose strength of 1 mg or 0.5 mg;  
 To determine the percentage of patients resuming a single background antihypertensive agent 
at 3, 6, 9, and 12 months; and 
 To determine the percentage of patients requiring rescue medication (with/without a single 
background antihypertensive agent) during study participation. 
2.2 
Effectiveness Objectives 
The effectiveness objectives are to evaluate the following relative to baseline (Visit 1) in 
Study CIN-107-130 over 52 weeks: 
 The mean SBP change; 
 The mean DBP change;  
 The percentage of patients achieving a seated SBP <130 mmHg;  
 The percentage of non-responders in Study CIN-107-124 achieving a seated SBP response 
<130 mmHg with CIN-107 (with/without a single background antihypertensive agent and/or 
rescue medication), irrespective of Study CIN-107-124 dose strength; and 
 The percentage of responders in Study CIN-107-124 maintaining a seated SBP response 
<130 mmHg with CIN-107 (with/without a single background antihypertensive agent and/or 
rescue medication), irrespective of Study CIN-107-124 dose strength. 

AstraZeneca  
Clinical Study Protocol D6971C00001
Confidential & Proprietary 
Page 27 of 66 
Version 2.0, 31 March 2023 
2.3 
Pharmacokinetic-Pharmacodynamic Objective 
The PK-PD objective is to evaluate exposure-response relationships of CIN-107 using measures 
of safety, PD, and/or effectiveness. 

AstraZeneca  
Clinical Study Protocol D6971C00001
Confidential & Proprietary 
Page 28 of 66 
Version 2.0, 31 March 2023 
3 
STUDY DESCRIPTION 
3.1 
Summary of Study Design 
This is a Phase 2, multicenter, OLE study to evaluate the long-term safety, tolerability, and 
effectiveness of CIN-107 for up to 52 weeks in patients with HTN who have completed Part 1 or 
Part 2 of Study CIN-107-124. The study will be conducted at clinical sites that have participated 
in the double-blind, Phase 2 Study CIN-107-124. Patients will be assigned the same patient 
number they have had in Study CIN-107-124.  
Written informed consent must be obtained before any Protocol-specific procedures are performed 
in this study (Study CIN-107-130). Eligible patients from Study CIN-107-124 who elect to 
participate in the OLE will be enrolled directly following the EOT assessments at the end of Part 1 
or Part 2 of Study CIN-107-124 (ie, they will not undergo the safety follow-up in 
Study CIN-107-124). The EOT assessments at the end of Part 1 or Part 2 of Study CIN-107-124 
will serve as the Day 1 pre-dose assessments for those enrolling in Study CIN-107-130.  
Enrolled patients will continue treatment with 2 mg CIN-107 tablets. The guiding principle for 
medical decision making with regard to BP management in the OLE study is to try to maintain 
patients on the highest dose of CIN-107 that is safe and medically reasonable. Investigators will 
be allowed to determine whether the patient should start the OLE study with an additional 
background antihypertensive (non-CIN-107) agent based on the patient s BP control in 
Study CIN-107-124 (ie, whether the patient in addition to the CIN-107 study drug would start the 
OLE study with an additional background antihypertensive agent from another or same class as 
during Part 1 of Study CIN-107-124).  
The background antihypertensive agent chosen at Visits 1 or 2 should remain stable until Visit 3 
of the OLE study, after which the Investigator is permitted to use his/her medical judgment to 
up/down titrate or discontinue the background antihypertensive (non-CIN-107) agent.  
Rescue medication use is permitted and recommended if the SBP shows an acute and sustained 
increase of 30 mmHg (or greater) from Visit 1 and/or is 
170 mmHg and/or the DBP is 
105 mmHg in office measurement. Investigators should use their best clinical judgment when 
determining the need for rescue medications and are encouraged to discuss selection of rescue 
medication with the study Medical Monitors. See Appendix E for rescue medication guidance. 
The Investigator is to document the clinical rationale for adding, changing dose, or discontinuing 
either the single background antihypertensive agent or rescue medication. The range of 
antihypertensive classes that may be used (listed in Appendix E) during this study is left to the 
-sparing diuretics and MRAs are not allowed. 
To manage persistent or symptomatic hypotension, the Investigator should first reduce or 
discontinue any rescue medication, and then reduce or discontinue use of the single background 
antihypertensive (non-CIN-107) agent if medically sound. If the symptoms continue, the dose 
strength of CIN-107 may be down-titrated from 2 mg to 1 mg. The CIN-107 dose may be further 
down-titrated to 0.5 mg if the SBP remains 100 mmHg for 3 consecutive days or if symptoms 
persist. CIN-107 may be temporarily discontinued if the SBP remains <90 mmHg for 
3 consecutive days or if symptoms persist. Study drug dosing may be resumed or up-titrated after 
reassessments. See Appendix F for guidance on down-titration of antihypertensive medication(s). 

AstraZeneca  
Clinical Study Protocol D6971C00001
Confidential & Proprietary 
Page 29 of 66 
Version 2.0, 31 March 2023 
Patients will complete approximately 8 study visits during the OLE study, including enrollment 
(Visit 1) and follow-up (Visit 8) visits. During the treatment period, patients will return to the 
clinical site for visits. Unscheduled visits may be scheduled at any time during the study period 
based on the 
participation of patients. 
The safety and tolerability of CIN-107 will be assessed from the day of the first dose of study drug 
in Study CIN-107-130 until the end of the follow-up visit. Patients will be followed for 
effectiveness and adherence throughout the treatment period. PD variables analyzed during the 
study may include, but are not limited to, measures of aldosterone and its precursors, cortisol and 
its precursor, and plasma renin activity (PRA), and calculation of aldosterone/PRA ratio. PK 
variables analyzed during the study will include plasma concentrations of CIN-107 and any 
measured metabolite(s). 
Clinical sites will provide patients with a 24-hour urine collection kit at Visit 6. Patients will be 
instructed to start the collection up to 3 days prior to Visit 7, refrigerate the collected sample, and 
bring the entire sample to the clinical site at Visit 7. A 24-hour urine collection will commence 
after the first morning void on the first day and will include the first morning void on the second 
day for a total duration of 24 (±2) hours. Patients must be instructed to keep the sample refrigerated 
at all times except during their transit to the clinical site. A 24-hour urine collection may be 
repeated if the Investigator suspects that the sampling is insufficient and the patient is within the 
visit window. Clinical sites will aliquot urine into a transfer tube and send it to the Central 
Laboratory. 
On clinical site visit days, patients will self-administer the morning dose of any other concomitant 
medications (if applicable) at home. CIN-107 should be withheld as it will be self-administered at 
the clinical site and witnessed by site staff, after completion of pre-dose evaluations and laboratory 
sampling. Between clinical site visits, patients will continue to self-administer study drug QD by 
mouth at approximately the same time each morning. Patients will be instructed to bring their 
antihypertensive medication(s) and study drug to all clinical site visits for pill counts. Patients 
should not exercise, smoke, or consume caffeinated beverages or food for at least 2 hours prior to 
each clinical site visit. All clinical site visits should occur between 6:00 a.m. and 11:00 a.m. 
3.2 
Study Indication 
CIN-107 is being studied for the long-term safety, tolerability, and effectiveness in the reduction 
of SBP in patients with HTN. 

AstraZeneca  
Clinical Study Protocol D6971C00001
Confidential & Proprietary 
Page 30 of 66 
Version 2.0, 31 March 2023 
4 
SELECTION AND WITHDRAWAL OF PATIENTS  
4.1 
Population 
Patients who participated in and completed Part 1 or Part 2 of Study CIN-107-124 and did not 
discontinue the study drug for any reason, including an AE, will be eligible for this study.  
4.2 
Inclusion Criteria 
Patients who meet all of the following criteria will be eligible to participate: 
1. Have completed Part 1 or Part 2 of Study CIN-107-124; 
Note: Patients who have completed Part 1 but were not eligible for Part 2 of 
Study CIN-107-124 may consent to Study CIN-107-130. 
2. Have had acceptable safety and tolerability during Study CIN-107-124 as determined by the 
Investigator or Medical Monitor;  
3. Have demonstrated 70% and 120% adherence to their single background antihypertensive 
agent and the CIN-107 placebo during Study CIN-107-124; 
4. Agree to comply with the contraception and reproduction restrictions of the study as follows: 
o Male patients must agree to abstain from sperm donation from Day 1 through 90 days after 
the final dose of study drug; 
o Female patients of childbearing potential (ie, ovulating, pre-menopausal, and not surgically 
sterile) must have a documented negative serum pregnancy test at enrollment (Visit 1); and 
o Female patients of childbearing potential must use a highly effective method of 
contraception (ie, <1% failure rate) from Day 1 through 30 days after the last administration 
of study drug. 
Note: Acceptable methods of contraception for female patients enrolled in the study 
include the following:  
 Surgical sterilization (eg, hysterectomy, bilateral oophorectomy, bilateral tubal 
ligation); 
 Intrauterine device for at least 12 weeks before enrollment (Visit 1); 
 Hormonal contraception (oral, implant, injection, ring, or patch) for at least 12 weeks 
before enrollment (Visit 1); or  
 Diaphragm used in combination with spermicide. 
Note: Postmenopausal female patients, who were either >60 years or had follicle-stimulating 
hormone (FSH) in the post-menopausal range during screening for Study CIN-107-124, must 
continue to have no menstrual bleeding for at least 1 year prior to enrollment (Visit 1), and 
therefore do not require FSH testing. 
5. Are able and willing to give informed consent for participation in the clinical study. 

AstraZeneca  
Clinical Study Protocol D6971C00001
Confidential & Proprietary 
Page 31 of 66 
Version 2.0, 31 March 2023 
4.3 
Exclusion Criteria 
Patients who meet any of the following criteria will be excluded from participation in the study: 
1. Have met Protocol-defined stopping criteria, were withdrawn from the study, discontinued 
CIN-107 at the time of Visits 6 or 9, or were not compliant with the Protocol during 
Study CIN-107-124;  
2. Have received treatment with any investigational agent for disease intervention (ie, other than 
study drug) during Study CIN-107-124, or since the last administration of study drug in 
Study CIN-107-124, or plans to participate in another clinical study within 30 days of 
discontinuation of study drug;  
3. Have had any new, significant, or uncontrolled comorbidity since initially enrolling in 
Study CIN-107-124 that would increase the risk of the patient in Study CIN-107-130, as 
determined by the Investigator;  
4. Have had a mean seated SBP 170 mmHg or DBP 105 mmHg at the end of Part 1 or Part 2 
of Study CIN-107-124; 
Note: Mean seated BP is defined as the average of 3 seated BP measurements.  
5. Have an upper arm circumference that does not meet the cuff measurement criteria for the 
selected BP machine at Visit 1 of Study CIN-107-130; 
6. Have any uncontrolled or clinically significant laboratory abnormality that would affect safety, 
interpretation of study d
, as determined by the 
Investigator; 
7. Have experienced a de novo or reactivated serious viral infection such as hepatitis B, 
hepatitis C, or HIV during Study CIN-107-124;  
Note: Patients who experienced a viral infection during Study CIN-107-124 (ie, seasonal flu, 
Coronavirus Disease 2019, etc) are not excluded if recovered and asymptomatic within 
4 weeks of Visit 1 in Study CIN-107-130. 
8. Have had any major episode of infection requiring hospitalization or treatment with 
intravenous antibiotics during Study CIN-107-124; 
9. Have developed a malignancy (with the exception of non-serious local and resectable basal or 
squamous cell carcinoma of the skin) during Study CIN-107-124; 
10. Have anticipated initiation of erythropoietin-stimulating agents and/or planned transfusion 
within 2 months after enrollment (Visit 1);  
11. Are expected to receive or are receiving any of the exclusionary drugs (strong CYP3A 
inducers; see Appendix D for examples); 
12. Have known secondary causes of HTN (eg, renal artery stenosis, uncontrolled or untreated 
hyperthyroidism, 
uncontrolled 
or 
untreated 
hypothyroidism, 
hyperparathyroidism, 
apnea; 
Note: Patients with primary aldosteronism CAN BE considered for enrollment unless an 
adrenalectomy is expected before the end of their participation in the study. 

AstraZeneca  
Clinical Study Protocol D6971C00001
Confidential & Proprietary 
Page 32 of 66 
Version 2.0, 31 March 2023 
13. Have been diagnosed with New York Heart Association stage III or IV chronic heart failure 
during Study CIN-107-124; 
14. Have had a stroke, transient ischemic attack, hypertensive encephalopathy, acute coronary 
syndrome, or hospitalization for heart failure during Study CIN-107-124; 
15. Have a known current severe left ventricular outflow obstruction, such as obstructive 
hypertrophic cardiomyopathy and/or severe aortic valvular disease diagnosed from a prior 
echocardiogram; 
16. Have a planned coronary revascularization (percutaneous coronary intervention [PCI] or 
coronary artery bypass graft [CABG]) or any major surgical procedure; 
17. Have had a CABG or other major cardiac surgery (eg, valve replacement), peripheral arterial 
bypass surgery, or PCI during Study CIN-107-124; 
18. Have a planned dialysis or kidney transplant during the course of this study; 
19. Have a known hypersensitivity to CIN-107 or drugs of the same class, or any of its excipients; 
20. Have any clinically relevant medical or surgical conditions (including unstable conditions 
and/or treatment with systemic immunosuppressants including corticosteroids) that, in the 
opinion of the Investigator, would put the patient at risk by participating in the study;  
21. Are pregnant, breastfeeding, or planning to become pregnant during the study; or  
22. Are considered to be unsuitable for any other reason that may either place the patient at 
increased risk during participation or interfere with the interpretation of the study outcomes by 
the Investigator, after reviewing medical and psychiatric history, physical examination, and 
laboratory evaluation. 
4.4 
Study Withdrawal and Study Drug Discontinuation Criteria 
A patient will be withdrawn from this clinical study for any of the following reasons: 
 The patient withdraws consent or requests discontinuation from the study for any reason; or 
 The study is terminated by the Sponsor or the regulatory authority. 
The study drug will be discontinued for any of the following reasons: 
 Occurrence of any medical condition or circumstance, SAE, clinically significant AE, severe 
laboratory abnormality, or intercurrent illness which exposes the patient to substantial risk, 
does not allow the patient to adhere to the requirements of the Protocol, and/or indicates to the 
Investigator that continued participation is not in the best interest of the patient; 
 Requirement of excluded concomitant medication and/or procedure; or 
 The patient becomes pregnant. 
If a patient withdraws prematurely from the study due to the above criteria or any other reason, 
he/she will be requested to undergo the Early Termination (ET) procedures, and site staff should 
make every effort to complete the full panel of assessments scheduled for EOT (Visit 7) at ET. 
The reason for patient withdrawal must be documented in the electronic case report form (eCRF). 

AstraZeneca  
Clinical Study Protocol D6971C00001
Confidential & Proprietary 
Page 33 of 66 
Version 2.0, 31 March 2023 
Patients who prematurely discontinue study drug treatment should complete the remaining study 
visits for safety monitoring despite discontinuation of study drug. 
Withdrawn patients will not be replaced.  

AstraZeneca  
Clinical Study Protocol D6971C00001
Confidential & Proprietary 
Page 34 of 66 
Version 2.0, 31 March 2023 
5 
STUDY TREATMENTS 
5.1 
Treatment Groups 
Eligible patients from Study CIN-107-124 who elect to participate in this study will continue 
treatment with 2 mg CIN-107 tablets QD after enrollment. 
5.2 
Rationale for Dosing 
The OLE Study CIN-107-130 was designed to assess the long-term treatment effect of the 2 mg 
dose of CIN-107 on safety, tolerability, and BP management in patients with HTN. It is anticipated 
that the dose strengths used in the parent Study CIN-107-124 of up to 2 mg will be well tolerated 
and effective in lowering the aldosterone level based on results of non-clinical toxicity studies and 
completed clinical pharmacology studies. 
Investigators will be allowed to determine whether the patient should start the OLE study with an 
additional single background antihypertensive (non-CIN-107) agent based on the patient s BP 
control in Study CIN-107-124 (ie, whether the patient in addition to the CIN-107 study drug would 
start the OLE study with an additional single background antihypertensive agent from another or 
same class as during Part 1 of Study CIN-107-124). Rescue medications may be used as detailed 
in Appendix E. Management of persistent or symptomatic hypotension is detailed in Appendix F. 
5.3 
Blinding 
This is an open-label study. There is no blinding of the study drug. 
5.4 
Drug Supplies 
5.4.1 
Formulation and Packaging 
The study drug, CIN-107 tablets, are round, white tablets exhibiting a >70% release of the CIN-107 
drug substance by 45 minutes in vitro. 
CIN-107 tablets will be provided in 0.5, 1, and 2 mg dose strengths. The tablets will be packaged 
in blister packs to achieve the doses required for the study.
 
5.4.2 
Study Drug Preparation and Dispensing 
5.4.2.1 
Background antihypertensive agent 
All patients who require a single background antihypertensive agent will receive it, unless 
requested otherwise, through a Central Pharmacy starting at Visit 1. Clinical sites will send 
prescriptions for background antihypertensive agent to the Central Pharmacy at least 1 week before 
the planned dispensation. 
5.4.2.2 
Study drug 
The study drug, open-label CIN-107, will be delivered from the Central Depot to the clinical site. 
Once a patient has been enrolled in the study and registered by Interactive Response Technology, 

AstraZeneca  
Clinical Study Protocol D6971C00001
Confidential & Proprietary 
Page 35 of 66 
Version 2.0, 31 March 2023 
site staff who have been delegated the task of drug dispensing by the Investigator will dispense the 
appropriate treatment at the scheduled visits (see Appendix A). 
Study drug dispensation may occur at any time starting at enrollment (Visit 1) and before EOT 
(Visit 7). A Study Reference Manual with details of study drug dispensation and collection of 
unused study drug will be provided to the clinical sites. 
5.4.3 
Study Drug Administration 
Eligible patients from Study CIN-107-124 who elect to participate in this study will continue 
treatment with 2 mg CIN-107 tablets QD after enrollment, starting at Visit 1 and concluding at 
EOT (Visit 7). 
On clinical site visit days, patients will self-administer the morning dose of any other concomitant 
medications (if applicable) at home. CIN-107 should be withheld as it will be self-administered at 
the clinical site and witnessed by site staff, after completion of pre-dose evaluations and laboratory 
sampling.  
Between clinical site visits, patients will continue to self-administer CIN-107 QD by mouth at 
approximately the same time each morning.  
5.4.4 
Treatment Compliance 
For all Protocol-specified doses when the patient is not at the clinical site, patients will 
self-administer CIN-107 at home. For doses that are administered at the clinical site, site staff will 
record the date and time of study drug administration.  
Site staff will also collect information from the patient about delays with taking the study drug and 
missed study drug doses over the 3 days prior to PK sampling and record the information in source 
files and eCRF. 
Patients will be instructed to bring their study drug and antihypertensive medication(s) to all 
clinical site visits. Site staff will calculate treatment adherence based on pill counts. Treatment 
compliance is defined as >70% and <120% over the course of the treatment period. If a trend of 
patient non-compliance is observed, then the patient may be discontinued based on the discretion 
of the Investigator (see Section 4.4). Individual missed doses or doses held due to abnormal 
laboratory values or AEs will not be reported as a deviation. 
Site staff will counsel patients about the importance of adhering to the following: study drug, 
background antihypertensive regimen (if applicable), as indicated in Appendix A. 
5.4.5 
Storage and Accountability 
The study drug will be stored at controlled room temperature of 20°C to 25°C (68°F to 77°F). 
Consistent with the United States Pharmacopeia references, excursions between 15°C and 30°C 
are allowed during storage. During transport, excursions up to 40°C are permissible for up to 
1 week. 
A Drug Accountability Log will be maintained by the clinical sites indicating the receipt and 
dispensation of all study drug supplies. The log will indicate date dispensed, quantity dispensed, 
and the patient to whom the study drug was dispensed. 

AstraZeneca  
Clinical Study Protocol D6971C00001
Confidential & Proprietary 
Page 36 of 66 
Version 2.0, 31 March 2023 
Patients deemed ineligible for the study at Visit 1 of Study CIN-107-130 will be asked to return 
the study drug (dispensed at Visit 1) to the clinical site in prepaid shipments and complete the 
safety follow-up in Study CIN-107-124. 
After calculating treatment adherence (by pill counts), site staff will collect any remaining study 
drug from the patient at the specified visits, and unused study drug will be destroyed at the clinical 
may return any unused study drug to the Central Depot for final drug accountability and 
authorization prior to return or destruction of the study drug, and that appropriate records of the 
disposal are documented and maintained. If no study drug remains, this will be indicated in the 
Drug Accountability Log. 
5.5 
Prior and Concomitant Medications and/or Procedures 
5.5.1 
Excluded Medications and/or Procedures 
Use of the following investigational, prescription, or over-the-counter medications or procedures 
is not permitted during the study: 
 Strong CYP3A inducers (examples are provided in Appendix D); 
 Chronic use of non-steroidal anti-inflammatory drugs; 
 MRA or a potassium-sparing diuretic as part of an existing antihypertensive regimen; 
 Potassium supplements; 
 Dialysis;  
 Kidney transplantation; 
 Erythropoietin-stimulating agents; 
 Transfusion of blood and blood products; or 
 Major surgical procedure. 
5.5.2 
Restricted Medications and/or Procedures 
Patients should not exercise, smoke, or consume caffeinated beverages or food for at least 2 hours 
prior to each clinical site visit. All clinical site visits should occur between 6:00 a.m. and 11:00 a.m. 
5.5.3 
Allowed Medications and/or Procedures 
Investigators will be allowed to determine whether the patient should start the OLE study with an 
additional background antihypertensive (non-CIN-107) agent based on the patient s BP control in 
Study CIN-107-124 (ie, whether the patient in addition to the CIN-107 study drug would start the 
OLE study with an additional background antihypertensive agent from another or same class as 
during Part 1 of Study CIN-107-124).  
The background antihypertensive agent chosen at Visits 1 or 2 should remain stable until Visit 3 
of the OLE study, after which the Investigator is permitted to use his/her medical judgment to 
up/down titrate or discontinue background antihypertensive (non-CIN-107) agent.  

AstraZeneca  
Clinical Study Protocol D6971C00001
Confidential & Proprietary 
Page 37 of 66 
Version 2.0, 31 March 2023 
The Investigator is to document the clinical rationale for adding, changing dose, or discontinuing 
either the background antihypertensive agent or rescue medication. The range of antihypertensive 
classes that may be used (listed in Appendix E
discretion, but potassium-sparing diuretics and MRAs are not allowed. 
Rescue medications (see Appendix E for guidance) and down-titration of antihypertensive 
medication(s) (see Appendix F for recommendations) are allowed. 
5.5.4 
Dietary Guidance 
Given the potential for predisposition to lower sodium values in the study population (eg, diuretic 
use) and to avoid potential additive effects on serum sodium values, Investigators should be 
cautious in advising patients to increase fluid intake/hydration during the study, as may sometimes 
be done prior to laboratory sampling. As such, patients should maintain their usual fluid intake as 
best as possible, unless additional oral hydration would be needed, such as in cases of assessed 
volume depletion or dehydration. In addition, Investigators should consider encouraging patients 
who present with lower sodium levels (eg, approximately 128 to 133 mEq/L) to moderately 
liberalize their salt intake without necessarily increasing fluid intake. 
5.5.5 
Documentation of Prior and Concomitant Medication Use 
All medications used within 30 days prior to enrollment (Visit 1) will be recorded.  
All concomitant medications and concurrent therapies (including fluids, electrolytes, vitamins, and 
 Appendix A. The dose, route, unit 
frequency of administration, indication for administration, and dates of medication administration 
will also be captured in source documents and on the appropriate eCRF. Clinical sites will record 
the time of concomitant medication administration (hour, minute) if the medication is initiated 
and/or stopped on the first study drug administration visit (Visit 1) or at EOT (Visit 7)/ET. 

AstraZeneca  
Clinical Study Protocol D6971C00001
Confidential & Proprietary 
Page 38 of 66 
Version 2.0, 31 March 2023 
6 
STUDY PROCEDURES 
The EOT assessments at the end of Part 1 or Part 2 of Study CIN-107-124 will serve as the Day 1 
pre-dose assessments for those enrolling in Study CIN-107-130. 
Study procedures will follow the Schedule of Procedures (see Appendix A). 

AstraZeneca  
Clinical Study Protocol D6971C00001
Confidential & Proprietary 
Page 39 of 66 
Version 2.0, 31 March 2023 
7 
EFFECTIVENESS ASSESSMENTS 
7.1 
Effectiveness Endpoints  
The effectiveness endpoints include the following: 
 Change from baseline in mean seated SBP with CIN-107 over the 52-week treatment period. 
Baseline mean seated SBP is the value at Visit 1 of Study CIN-107-130; 
 Change from baseline in mean seated DBP with CIN-107 over the 52-week treatment period. 
Baseline mean seated DBP is the value at Visit 1 of Study CIN-107-130;  
 The percentage of patients achieving a seated SBP response <130 mmHg with CIN-107 
monotherapy without a single background antihypertensive agent over the 52-week treatment 
period; 
 The percentage of non-responders in Study CIN-107-124 achieving a seated SBP response 
<130 mmHg with CIN-107 (with/without a single background antihypertensive agent and/or 
rescue medication), irrespective of Study CIN-107-124 dose strength; 
 The percentage of responders in Study CIN-107-124 maintaining a seated SBP response 
<130 mmHg with CIN-107 (with/without a single background antihypertensive agent and/or 
rescue medication), irrespective of Study CIN-107-124 dose strength;  
 PD variables analyzed during the study, including measures of aldosterone and its precursors, 
cortisol and its precursor, and PRA, and calculated aldosterone/PRA ratio; and 
 PK variables analyzed during the study, including plasma concentrations of CIN-107 and any 
measured metabolite(s). 
7.2 
Pharmacokinetic and Pharmacodynamic Assessment 
The PK-PD objective is to evaluate exposure-response relationships of CIN-107 using measures 
of safety, PD, and/or effectiveness.  
7.2.1 
Pharmacodynamic Blood Sampling 
Pre-dose blood samples for PD analysis will be collected at the visits specified in Appendix A. 
The actual date and time of collection of each PD sample will be recorded. PD blood samples will 
be collected in the morning at the clinical site, after the patient has been out of bed for 
approximately 2 hours and has been seated for 5 to 15 minutes. Samples will be analyzed using 
validated methods, as appropriate. Additional details including PD sample collection, processing, 
facility, and shipment can be found in the Laboratory Manual. 
7.2.2 
Twenty-Four-Hour Urine Collection 
Kits for 24-hour urine collection will be provided, and 24-hour urine samples will be obtained as 
specified in Appendix A.  
A 24-hour urine collection will commence after the first morning void on the first day and will 
include the first morning void on the second day for a total duration of 24 ±2 hours. Patients must 
be instructed to keep the sample refrigerated at all times expect during their transit to the clinical 
site. A 24-hour urine collection may be repeated if the Investigator suspects that the sampling is 

AstraZeneca  
Clinical Study Protocol D6971C00001
Confidential & Proprietary 
Page 40 of 66 
Version 2.0, 31 March 2023 
insufficient and the patient is within the visit window. Clinical sites will aliquot urine into a transfer 
tube and send it to the Central Laboratory.  
The analytes that will be measured in the 24-hour urine collection samples are provided 
Appendix B. 
7.3 
Pharmacokinetic Assessments 
PK variables to be analyzed during the study will include plasma concentrations of CIN-107 and 
any measured metabolite(s) (Appendix B). 
Pre-dose blood samples for PK analysis will be collected within approximately 15 minutes prior 
to dosing at the visits specified in Appendix A. The actual date and time of collection of each 
PK sample will be recorded. Site staff will collect information about delays with taking the study 
drug and missed study drug doses over the 3 days prior to PK sampling from the patient and record 
the information in source files and eCRF. 
Samples will be analyzed using validated liquid chromatography mass spectrometry methods. 
Analysis will be performed by Medpace Bioanalytical Laboratories, LLC.  
Additional details regarding PK sample collection, processing, and shipment can be found in the 
Laboratory Manual. 

AstraZeneca  
Clinical Study Protocol D6971C00001
Confidential & Proprietary 
Page 41 of 66 
Version 2.0, 31 March 2023 
8 
SAFETY AND TOLERABILITY ASSESSMENTS 
The safety and tolerability of CIN-107 will be assessed from the day of the first dose of study drug 
in Study CIN-107-130 until the end of the follow-up visit. The safety and tolerability endpoints 
will include the following: 
 TEAEs; 
 Treatment-emergent SAEs; 
 TEAEs of special interest; 
 TEAEs leading to premature discontinuation of study drug; 
 Treatment-emergent marked laboratory abnormalities;  
 Change on standing SBP and DBP, measured pre-dose at the clinical site, from 
baseline (Visit 1) of Study CIN-107-130 to EOT (Visit 7);  
 Vital signs, standing BP and heart rate, physical examinations, ECGs, body weight, and clinical 
laboratory evaluations, including standard safety chemistry panel, hematology, coagulation, 
and urinalysis; 
 The percentage of patients with electrolyte imbalance; 
 The percentage of laboratory results with electrolyte imbalance; 
 The percentage of patients requiring down-titration of CIN-107 from the maximal dose 
strength of 2 mg to a lower dose strength of 1 mg or 0.5 mg;  
 The percentage of patients resuming a single background antihypertensive agent at 3, 6, 9, and 
12 months; and 
 The percentage of patients requiring rescue medication (with/without a single background 
antihypertensive agent) during study participation. 
8.1 
Adverse Events 
An AE is defined as any untoward medical occurrence in a clinical investigation subject 
administered a pharmaceutical product, which does not necessarily have a causal relationship with 
this treatment. An AE can therefore be any unfavorable and/or unintended sign (including an 
abnormal laboratory finding), symptom, or disease temporally associated with the use of an 
investigational medicinal product, whether or not related to the investigational medicinal product. 
All AEs, including observed or volunteered problems, complaints, or symptoms, are to be recorded 
on the appropriate eCRF. 
AEs, which include clinical laboratory test variables, will be monitored and documented from the 
day of the first dose of study drug in Study CIN-107-130 until the end of the follow-up visit. 
Patients should be instructed to report any AE that they experience to the Investigator, whether or 
not they think the event is due to study drug. Beginning from the day of the first dose of study drug 
in Study CIN-107-130 until the end of the follow-up visit, Investigators should make an 
assessment for AEs at each visit and record the event on the appropriate AE eCRF.  
Wherever possible, a specific disease or syndrome rather than individual associated signs and 
symptoms should be identified by the Investigator and recorded on the eCRF. However, if an 

AstraZeneca  
Clinical Study Protocol D6971C00001
Confidential & Proprietary 
Page 42 of 66 
Version 2.0, 31 March 2023 
observed or reported sign or symptom is not considered a component of a specific disease or 
syndrome by the Investigator, it should be recorded as a separate AE on the eCRF. Additionally, 
the condition that led to a medical or surgical procedure (eg, surgery, endoscopy, tooth extraction, 
or transfusion) should be recorded as an AE, not the procedure itself.  
Any medical condition already present at enrollment (Visit 1) should be recorded as medical 
history and not be reported as an AE unless the medical condition or signs or symptoms present at 
baseline changes in severity, frequency, or seriousness at any time during the study. In this case, 
it should be reported as an AE. 
Clinically significant abnormal laboratory or other examination (eg, ECGs) findings that are 
detected during the study or are present at enrollment (Visit 1) and significantly worsen during the 
study should be reported as AEs, as described below. The Investigator will exercise his or her 
medical and scientific judgment in deciding whether an abnormal laboratory finding or other 
abnormal assessment is clinically significant. Clinically significant abnormal laboratory values 
occurring during the clinical study will be followed until repeat tests return to normal, stabilize, or 
are no longer clinically significant. Abnormal test results that are determined to be an error should 
not be reported as an AE. Laboratory abnormalities or other abnormal clinical findings (eg, ECG 
abnormalities) should be reported as an AE if any of the following are applicable: 
 If an intervention is required as a result of the abnormality; 
 If action taken with the study drug is required as a result of the abnormality; or 
 Based on the clinical judgment of the Investigator. 
8.1.1 
Adverse (Drug) Reaction 
All noxious and unintended responses to a medicinal product related to any dose should be 
relationship between a medicinal product and an AE is at least a reasonable possibility, ie the 
relationship cannot be ruled out. 
8.1.2 
Unexpected Adverse Drug Reaction 
An Unexpected Adverse Drug Reaction is defined as an adverse reaction, the nature or severity of 
which is not consistent with the applicable product information. 
8.1.3 
Assessment of Adverse Events by the Investigator 
The Investigator will assess the severity (intensity) of each AE as mild, moderate, or severe, and 
will also categorize each AE as to its potential relationship to study drug using the categories of 
yes or no. 
Assessment of severity 
Mild  An event that is easily tolerated and generally not interfering with normal daily activities. 
Moderate  An event that is sufficiently discomforting to interfere with normal daily activities. 
Severe  An event that is incapacitating with inability to work or perform normal daily activities. 

AstraZeneca  
Clinical Study Protocol D6971C00001
Confidential & Proprietary 
Page 43 of 66 
Version 2.0, 31 March 2023 
Causality assessment 
The relationship of an AE to the administration of the study drug is to be assessed according to the 
following definitions: 
No (unrelated, not related, unlikely to be related)  The time course between the administration of 
study drug and the occurrence or worsening of the AE rules out a causal relationship and another 
cause (concomitant drugs, therapies, complications, etc) is suspected. 
Yes (possibly, probably, or definitely related)  The time course between the administration of 
study drug and the occurrence or worsening of the AE is consistent with a causal relationship and 
no other cause (concomitant drugs, therapies, complications, etc) can be identified. 
The definition implies a reasonable possibility of a causal relationship between the event and the 
study drug. This means that there are facts (evidence) or arguments to suggest a causal relationship. 
The following factors should also be considered: 
 The temporal sequence from study drug administration- 
The event should occur after the study drug is given. The length of time from study drug 
exposure to event should be evaluated in the clinical context of the event. 
 Underlying, concomitant, intercurrent diseases- 
Each report should be evaluated in the context of the natural history and course of the 
disease being treated and any other disease the patient may have. 
 Concomitant drug- 
The other drugs the patient is taking or the treatment the patient receives should be 
examined to determine whether any of them might be recognized to cause the event in 
question. 
 Known response pattern for this class of study drug- 
Clinical and/or preclinical data may indicate whether a particular response is likely to be a 
class effect. 
 Exposure to physical and/or mental stresses- 
The exposure to stress might induce adverse changes in the recipient and provide a logical 
and better explanation for the event. 
 The pharmacology and PK of the study drug- 
The known pharmacologic properties (absorption, distribution, metabolism, and excretion) 
of the study drug should be considered. 
8.1.4 
Adverse Events of Special Interest 
The Investigator will monitor each patient for clinical and laboratory evidence of pre-defined AEs 
ipation in this study.  
The Investigator/designee will assess and report any additional information on the AESI in detail 
on the appropriate AE eCRF which must be reported within 24 hours of awareness of the event. 

AstraZeneca  
Clinical Study Protocol D6971C00001
Confidential & Proprietary 
Page 44 of 66 
Version 2.0, 31 March 2023 
For this study, AESIs include the following: 
 Events of hypotension that require clinical intervention; 
 Abnormal potassium laboratory values that require clinical intervention; and 
 Abnormal sodium laboratory values that require clinical intervention. 
During the course of the study, additional AESIs may be identified by the Sponsor. 
8.2 
Serious Adverse Events 
An AE or adverse reaction is considered serious if, in the view of either the Investigator or Sponsor, 
it results in any of the following outcomes: 
 Death; 
 A life-threatening AE; 
Note: An AE 
-
Investigator or Sponsor, its occurrence places the patient at immediate risk of death. It does 
not include an event that, had it occurred in a more severe form, might have caused death. 
 Requires hospitalization or prolongation of existing hospitalizations; 
Note: Any hospital admission with at least one overnight stay will be considered an inpatient 
hospitalization. An emergency room or urgent care visit without hospital admission will not 
be recorded as an SAE under this criterion, nor will hospitalization for a procedure scheduled 
or planned before signing of informed consent, or elective treatment of a pre-existing condition 
that did not worsen from baseline. However, unexpected complications and/or prolongation of 
hospitalization that occur during elective surgery should be recorded as AEs and assessed for 
seriousness. Admission to the hospital for social or situational reasons (ie, no place to stay, live 
too far away to come for hospital visits, respite care) will not be considered inpatient 
hospitalizations.  
 A persistent or significant disability/incapacity or substantial disruption of the ability to 
conduct normal life functions; 
 A congenital anomaly/birth defect; or 
 An important medical event. 
Note: Important medical events that do not meet any of the above criteria may be considered 
an SAE when, based upon appropriate medical judgment, they may jeopardize the patient and 
may require medical or surgical intervention to prevent one of the outcomes listed above. 
Examples of such medical events include allergic bronchospasm requiring intensive treatment 
in an emergency room or at home, blood dyscrasias or convulsions that do not result in 
inpatient hospitalizations, or the development of drug dependency. 
8.3 
Serious Adverse Event Reporting  Procedures for Investigators 
Initial reports 
All SAEs occurring from the time of informed consent until 30 days following the last 
administration of study drug must be reported to Medpace Clinical Safety within 24 hours of the 

AstraZeneca  
Clinical Study Protocol D6971C00001
Confidential & Proprietary 
Page 45 of 66 
Version 2.0, 31 March 2023 
knowledge of the occurrence. After the 30-day reporting window, any SAE that the Investigator 
considers related to study drug must be reported to the Medpace Clinical Safety or the 
Sponsor/designee. 
To report the SAE, complete the SAE eCRF electronically in the electronic data capture (EDC) 
system for the study. When the form is completed, Medpace Safety personnel will be notified 
electronically by the EDC system and will retrieve the form. If the event meets serious criteria and 
it is not possible to access the EDC system, send an email to Medpace Safety at 
medpace-safetynotification@medpace.com or call the Medpace SAE reporting line (phone 
number listed below), and fax/email the completed paper SAE form to Medpace (contact 
information listed in Section 8.7) within 24 hours of awareness. When the EDC system becomes 
available, the SAE information must be entered within 24 hours of the system becoming available. 
Follow-up reports 
The Investigator must continue to follow the patient until the SAE has subsided or until the 
condition becomes chronic in nature, stabilizes (in the case of persistent impairment), or the patient 
dies. 
Within 24 hours of receipt of follow-up information, the Investigator must update the SAE form 
electronically in the EDC system for the study and submit any supporting documentation (eg, 
patient discharge summary or autopsy reports) to Medpace Clinical Safety via fax or email. If it is 
not possible to access the EDC system, refer to the procedures outlined above for initial reporting 
of SAEs. 
8.4 
Overdose Reporting 
Overdose refers to the administration of a quantity of the study drug given per administration or 
cumulatively (accidentally or intentionally), which is above the maximum recommended dose 
according to the Protocol.  
In cases of a discrepancy in the drug accountability, overdose will be established only when it is 
clear that the patient has taken additional dose(s), or the Investigator has reason to suspect that the 
patient has taken additional dose(s). Clinical judgment should always be applied in determining 
overdose. 
All reports of overdose as described above must be reported on the Special Situations Report form 
and faxed/emailed to Medpace Clinical Safety (contact information listed in Section 8.7) within 
24 hours of knowledge of the event. All AEs associated with these Special Situation reports should 
be reported as AEs or SAEs as well as recorded on the AE eCRF and/or the SAE report form. 
Details of the symptoms and signs, clinical management, and outcome should be provided, when 
available. 
8.5 
Safety Surveillance and Management of Serum Potassium Levels 
Patient serum potassium levels will be monitored systematically throughout the study. Serum 
potassium will be measured at the Central Laboratory at each visit as indicated in the Schedule of 
Procedures (Appendix A). Unscheduled assessments of serum potassium levels should be 
-up from 
elevated Central Laboratory potassium, acute changes in clinical condition, suspected 
dehydration, etc).  

AstraZeneca  
Clinical Study Protocol D6971C00001
Confidential & Proprietary 
Page 46 of 66 
Version 2.0, 31 March 2023 
For serum potassium 5.5 mEq/L and <6 mEq/L, the patient should present to the clinical site 
immediately for repeat testing, but study drug dosing may continue. For serum potassium 
6 mEq/L, the patient should suspend study drug dosing and present to the clinical site 
immediately for repeat testing. 
Repeat and unscheduled testing for serum potassium should be measured at the local laboratory 
and Central Laboratory. 
8.6 
Pregnancy Reporting 
If a patient becomes pregnant during the study or within the safety follow-up period defined in the 
Protocol, the Investigator is to stop dosing with study drug(s) immediately and the patient should 
be withdrawn from the study. ET procedures should be implemented at that time.  
A pregnancy is not considered to be an AE or SAE; however, it must be reported to Medpace 
Clinical Safety within 24 hours of knowledge of the event. Medpace Clinical Safety will then 
provide the Investigator/clinical site the Exposure In Utero (EIU) form for completion. The 
Investigator/clinical site must complete the EIU form and fax/email it back to Medpace Clinical 
Safety.  
If the female partner of a male patient becomes pregnant while the patient is receiving study drug 
or within the safety follow-up period defined in the Protocol, the Investigator should notify 
Medpace Clinical Safety as described above.  
The pregnancy should be followed until the outcome of the pregnancy, whenever possible. Once 
the outcome of the pregnancy is known, the EIU form should be completed and faxed/emailed to 
Medpace Clinical Safety. If the outcome of the pregnancy meets the criteria for immediate 
classification as an SAE (ie, postpartum complication, spontaneous abortion, stillbirth, neonatal 
death, or congenital anomaly), the Investigator should follow the procedures for reporting an SAE. 
8.7 
Expedited Reporting 
The Sponsor/designee will report all relevant information about Suspected Unexpected Serious 
Adverse Reactions (SUSARs) that are fatal or life-threatening as soon as possible to the Food and 
Drug Administration (FDA), applicable competent authorities in all the Member States concerned, 
and to the Central Ethics Committee, and in any case no later than 7 days after knowledge by the 
Sponsor/designee of such a case. Relevant follow-up information will subsequently be 
communicated within an additional 8 days.  
All other SUSARs will be reported to the FDA, applicable competent authorities concerned and to 
the Central Ethics Committee concerned as soon as possible but within a maximum of 15 days of 
first knowledge by the Sponsor/designee.  
The Sponsor/designee will also report any additional expedited safety reports required in 
accordance with the timelines outlined in country-specific legislation.  
The Sponsor/designee will also inform all Investigators as required per local regulation. 
The requirements above refer to the requirements relating to investigational medicinal product. 

AstraZeneca  
Clinical Study Protocol D6971C00001
Confidential & Proprietary 
Page 47 of 66 
Version 2.0, 31 March 2023 
Safety Contact Information: Medpace Clinical Safety 
Medpace SAE reporting line  USA: 
8.8 
Clinical Laboratory Evaluations 
Blood samples for standard safety chemistry panel, hematology, and coagulation and urine 
samples for urinalysis will be obtained as indicated in Appendix A and assessed at the Central 
Laboratory per institutional guidelines.  
The complete list of analytes is available in Appendix B. 
A serum pregnancy test will be performed for female patients of childbearing potential as indicated 
in Appendix A. 
8.9 
Vital Signs 
Vital signs will include heart rate, respiratory rate, and body temperature. Orthostatic vitals will 
include standing BP and standing heart rate. Vital signs and BP will be measured pre-dose at visits 
indicated in Appendix A using the following standardized procedures: 
 Patients should not exercise, smoke, or consume caffeinated beverages or food for at least 
2 hours prior to each clinical site visit; 
 At clinical site visits when study drug will be administered, vital signs and BP will be assessed 
pre-dose only; 
 Vital signs and BP measurements should be obtained prior to ECG recordings; 
 Patient should be seated for at least 5 minutes in the examination room before measurement of 
vital signs and BP; and 
 For measuring BP during clinical site visits, the following standardized procedures are 
recommended: 
o The patient should be seated with his/her back supported, feet flat on the floor, and the 
measurement arm supported so that the midpoint of the manometer cuff is at heart level; 
o A designated automated office BP monitoring (AOBPM) device will be provided to each 
clinical site and must be used for all study-related measurements; 
o An appropriately sized cuff should be used with the bladder centered over the brachial 
artery; 
o The cuff size and arm used for the measurement should be recorded; 
o At enrollment (Visit 1), laterality should be determined first before taking the enrollment 
(Visit 1) measurements. BP will be measured in both upper arms (3 times/arm) using an 
appropriately sized cuff to detect possible laterality differences. The arm with the higher 
mean value will then be used to take the enrollment (Visit 1) BP measurements (at least 
5 minutes after determining laterality) and for all subsequent measurements; 

AstraZeneca  
Clinical Study Protocol D6971C00001
Confidential & Proprietary 
Page 48 of 66 
Version 2.0, 31 March 2023 
o All BP measurements should be obtained at approximately the same time of day as the 
enrollment (Visit 1) measurements are obtained; 
o 3 seated BP measurements (each measurement 1 to 2 minutes apart) should be obtained 
using the same arm and the AOBPM device at each clinical site visit; 
o If the lowest and highest SBP measurements are >15 mmHg apart, 3 additional readings 
should be performed after waiting 2 to 5 minutes for 6 total measurements. If the lowest 
and highest SBP measurements are >20 mmHg apart after a total of 6 measurements, the 
measurements will not be used to assess study eligibility but may be reassessed after at 
least 72 hours. If the lowest and highest SBP values remain >20 mmHg apart after 
6 measurements at a subsequent assessment, then the patient will be excluded from the 
study; and 
o Once the seated BP has been determined, the patient will be asked to stand, and after 
60 seconds, a single standing BP and heart rate (orthostatic vital signs) measurement will 
be obtained, as required. 
8.10 
Electrocardiograms 
Standard 12-lead ECGs will be performed at visits indicated in Appendix A. 
ECGs will be performed after the patient has been resting in the supine position for at least 
10 minutes and after measuring vital signs and BP. Twelve-lead ECGs will be printed and will be 
interpreted as soon as possible by a qualified Investigator (or Sub-Investigator) for the presence of 
abnormalities. 
Standard ECG parameters will be measured, and the following ECG parameters will be recorded: 
 QRS interval; 
 Heart rate; 
 PR interval: 
 RR interval; 
 QT interval; and 
 QTc (QTcF). 
Investigators should contact the Sponsor or designee if any clinically meaningful changes from 
baseline are noted on review. See Appendix C for ECG alert criteria guidance. 
8.11 
Physical Examination  
A complete physical examination will consist of general appearance, skin, head, eyes, ears, mouth, 
oropharynx, neck, heart, lungs, abdomen, extremities, and neuromuscular system at the visits 
indicated in Appendix A. 
A limited physical examination will consist of a minimum of general appearance, skin, heart, 
lungs, and abdomen at the visits indicated in Appendix A. 

AstraZeneca  
Clinical Study Protocol D6971C00001
Confidential & Proprietary 
Page 49 of 66 
Version 2.0, 31 March 2023 
8.12 
Body Measurement 
Body measurements to be collected include weight, height, body mass index (BMI), and upper 
arm circumference.  
Height will be collected at enrollment (Visit 1) only and will be used to calculate BMI at 
subsequent visits.  
Weight will be measured at the visits indicated in Appendix A. Weight will be measured with the 
 
entered into the EDC system, the system will compute the BMI. 
Upper arm circumference will be measured at enrollment (Visit 1) to ensure that the cuff 
measurement criteria for the selected BP machine is met. 

AstraZeneca  
Clinical Study Protocol D6971C00001
Confidential & Proprietary 
Page 50 of 66 
Version 2.0, 31 March 2023 
9 
STATISTICS 
Study CIN-107-130 is a multicenter, single arm, OLE study. The primary objective of this study 
is to assess the long-term safety and tolerability of CIN-107 in patients with HTN who have 
completed the parent Study CIN-107-124. 
The baseline values for safety and tolerability endpoints and effectiveness endpoints are defined 
as the values at Visit 1 prior to starting the first dose in Study CIN-107-130.  
No formal hypothesis testing is planned. Additional details of analyses to be performed will be 
specified in the Statistical Analysis Plan. 
9.1 
Analysis Populations 
The Safety Population will be the primary population used for analyses. The Safety Population 
includes any patients enrolled in Study CIN-107-130 who have taken at least 1 dose of any study 
drug.  
9.2 
Statistical Methods 
9.2.1 
Analysis of Safety 
All safety and tolerability endpoints will be summarized descriptively. The Safety Population will 
be the primary population used for analyses. 
9.2.2 
Analysis of Effectiveness 
9.2.2.1 
Analysis of effectiveness endpoints 
The effectiveness endpoints are secondary endpoints of this study. The change from baseline over 
time will be analyzed. The analyses will be performed descriptively based on data in the Safety 
Population. 
9.2.2.2 
Other effectiveness analyses 
Additional analyses may be conducted with data collected in the parent Study CIN-107-124 to 
assess safety, tolerability, and effectiveness of CIN-107 from the first exposure. 
9.2.3 
Interim Analysis 
No interim analysis is planned. 
9.2.4 
Sample Size Determination 
The study sample size is predicated on the overall size of the parent Study CIN-107-124. It is 
estimated that about 200 patients will enroll in this study. 

AstraZeneca  
Clinical Study Protocol D6971C00001
Confidential & Proprietary 
Page 51 of 66 
Version 2.0, 31 March 2023 
10 
DATA MANAGEMENT AND RECORD KEEPING 
10.1 
Data Management 
10.1.1 
Data Handling 
Data will be recorded at the clinical site on eCRFs and reviewed by the clinical research associate 
(CRA) during monitoring visits. The CRAs will verify data recorded in the EDC system with 
source documents. All corrections or changes made to any study data must be appropriately tracked 
in an audit trail in the EDC system. An eCRF will be considered complete when all missing, 
incorrect, and/or inconsistent data have been accounted for. 
10.1.2 
Computer Systems 
Data will be processed using a validated computer system conforming to regulatory requirements. 
10.1.3 
Data Entry 
Data must be recorded using the EDC system as the study is in progress. All site personnel must 
log into the system using their secure user name and password in order to enter, review, or correct 
study data. These procedures must comply with Title 21 of the Code of Federal Regulations 
(21 CFR Part 11) and other appropriate international regulations. All passwords will be strictly 
confidential. 
10.1.4 
Medical Information Coding 
For medical information, the following thesauri will be used: 
 Medical Dictionary for Regulatory Activities (latest) for medical history and AEs; and 
 World Health Organization Drug Dictionary for prior and concomitant medications. 
10.1.5 
Data Validation 
Validation checks programmed within the EDC system, as well as supplemental validation 
performed via review of the downloaded data, will be applied to the data in order to ensure 
accurate, consistent, and reliable data. Data identified as erroneous, or data that are missing, will 
be referred to the clinical site for resolution through data queries. 
The eCRFs must be reviewed and electronically signed by the Investigator. 
10.2 
Record Keeping 
Records of patients, source documents, monitoring visit logs, eCRFs, inventory of study product, 
regulatory documents, and other Sponsor correspondence pertaining to the study must be kept in 
the appropriate study files at the clinical site. Source data are defined as all information in original 
records and certified copies of original records of clinical findings, observations, or other activities 
in a clinical study necessary for the evaluation and reconstruction of the clinical study. Source data 
are contained in source documents (original records or certified copies). These records will be 
retained in a secure file for the period as set forth in the Clinical Study Agreement. Prior to transfer 
or destruction of these records, the Sponsor must be notified in writing and be given the 
opportunity to further store such records.  

AstraZeneca  
Clinical Study Protocol D6971C00001
Confidential & Proprietary 
Page 52 of 66 
Version 2.0, 31 March 2023 
10.3 
End of Study 
Protocol-specified 
visit/assessment for the last patient in the study. 

AstraZeneca  
Clinical Study Protocol D6971C00001
Confidential & Proprietary 
Page 53 of 66 
Version 2.0, 31 March 2023 
11 
INVESTIGATOR REQUIREMENTS AND QUALITY CONTROL  
11.1 
Ethical Conduct of the Study 
Good Clinical Practice (GCP) is an international ethical and scientific quality standard for 
designing, conducting, recording, and reporting studies that involve human patients. Compliance 
with this standard provides public assurance that the rights, safety, and wellbeing of study patients 
are protected, consistent with the principles that have their origin in the Declaration of Helsinki, 
and that the clinical study data are credible. 
11.2 
Institutional Review Board/Independent Ethics Committee 
The Institutional Review Board (IRB) will review all appropriate study documentation in order to 
safeguard the rights, safety, and well-being of patients. The study will only be conducted at clinical 
sites where IRB approval has been obtained. The P
informed 
consent form (ICF), advertisements (if applicable), written information given to the patients, safety 
updates, annual progress reports, and any revisions to these documents will be provided to the IRB 
by the Investigator. 
Federal regulations and International Council for Harmonisation (ICH) Guidelines require that 
approval be obtained from an IRB prior to participation of patients in research studies. Prior to 
study onset, the Protocol, any Protocol amendments, ICFs, advertisements to be used for patient 
recruitment, and any other written information regarding this study to be provided to a patient or 
patient
 
No drug will be released to the clinical site for dosing until written IRB authorization has been 
received by the Sponsor. 
11.3 
Informed Consent 
The ICF and any changes to the ICF made during the course of the study must be agreed to by the 
Sponsor or designee and the IRB prior to its use and must be in compliance with all ICH GCP, 
local regulatory requirements, and legal requirements. 
The Investigator must ensure that each study patient is fully informed about the nature and 
objectives of the study and possible risks associated with participation and must ensure that the 
patient has been informed of his/her rights to privacy. The Investigator will obtain written informed 
consent from each patient before any study-specific activity is performed and should document in 
the source documentation that consent was obtained prior to enrollment in the study. The original 
signed copy of the ICF must be maintained by the Investigator and is subject to inspection by a 
representative of the Sponsor, their representatives, auditors, the IRB, and/or regulatory agencies. 
A copy of the signed ICF will be given to the patient. 
11.4 
Study Monitoring Requirements 
It is the responsibility of the Investigator to ensure that the study is conducted in accordance with 
the Protocol, Declaration of Helsinki, ICH GCP, and applicable regulatory requirements, and that 
valid data are entered into the eCRFs. 
To achieve this objective, the CRA
the 
Sponsor in the maintenance of complete, legible, well organized, and easily retrievable data. 
Before the enrollment of any patient in this study, the Sponsor or their designee will review with 

AstraZeneca  
Clinical Study Protocol D6971C00001
Confidential & Proprietary 
Page 54 of 66 
Version 2.0, 31 March 2023 
the Investigator and site personnel the following documents: P
eCRFs, and procedures for their completion, informed consent process, and the procedure for 
reporting SAEs. 
The Investigator will permit the Sponsor or their designee to monitor the study as frequently as 
deemed necessary to determine that data recording and Protocol adherence are satisfactory. During 
the monitoring visits, information recorded on the eCRFs will be verified against source 
documents and requests for clarification or correction may be made. After the eCRF data is entered 
by the clinical site, the CRA will review the data for safety information, completeness, accuracy, 
and logical consistency. Computer programs that identify data inconsistencies may be used to help 
monitor the clinical study. If necessary, requests for clarification or correction will be sent to 
Investigators. The Investigator and his/her staff will be expected to cooperate with the CRA and 
provide any missing information, whenever possible. 
All monitoring activities will be reported and archived. In addition, monitoring visits will be 
documented at the clinical site by signature and date on the study-specific monitoring log. 
11.5 
Disclosure of Data 
Data generated by this study must be available for inspection by the FDA, the Sponsor or their 
designee, applicable foreign health authorities, and the IRB as appropriate. Patients or their legal 
representatives may request their medical information be given to their personal physician or other 
appropriate medical personnel responsible for their welfare. 
Patient medical information obtained during the study is confidential and disclosure to third parties 
other than those noted above is prohibited. 
11.6 
Retention of Records 
To enable evaluations and/or audits from regulatory authorities or the Sponsor, the Investigator 
will keep records, including the identity of all participating patients (sufficient information to link 
records, eg, eCRFs and hospital records), all original signed ICFs, copies of all eCRFs, SAE forms, 
source documents, and detailed records of treatment disposition. The records should be retained 
by the Investigator according to specifications in the ICH guidelines, local regulations, or as 
specified in the Clinical Study Agreement, whichever is longer. The Investigator must obtain 
written permission from the Sponsor before disposing of any records, even if retention 
requirements have been met. 
If the Investigator relocates, retires, or for any reason withdraws from the study, the Sponsor should 
be prospectively notified. The study records must be transferred to an acceptable designee, such 
as another Investigator, another institution, or to the Sponsor. 
11.7 
Publication Policy 
Following completion of the study, the data may be considered for publication in a scientific 
journal or for reporting at a scientific meeting. Each Investigator is obligated to keep data 
pertaining to the study confidential. The Investigator must consult with the Sponsor before any 
study data are submitted for publication. The Sponsor reserves the right to deny publication rights 
until mutual agreement on the content, format, interpretation of data in the manuscript, and journal 
selected for publication are achieved. 

AstraZeneca  
Clinical Study Protocol D6971C00001
Confidential & Proprietary 
Page 55 of 66 
Version 2.0, 31 March 2023 
11.8 
Financial Disclosure 
Investigators are required to provide financial disclosure information to the Sponsor to permit the 
Sponsor to fulfill its obligations under 21 CFR Part 54. In addition, Investigators must commit to 
promptly updating this information if any relevant changes occur during the study and for a period 
of 1 year after the completion of the study. 

AstraZeneca  
Clinical Study Protocol D6971C00001
Confidential & Proprietary 
Page 56 of 66 
Version 2.0, 31 March 2023 
12 
STUDY ADMINISTRATIVE INFORMATION 
12.1 
Protocol Amendments 
Any amendments to the study Protocol will be communicated to the Investigators by Medpace or 
the Sponsor. All Protocol amendments will undergo the same review and approval process as the 
original Protocol. A Protocol amendment may be implemented after it has been approved by the 
IRB, unless immediate implementation of the change is necessary for patient safety. In this case, 
the situation must be documented and reported to the IRB within 5 working days. 
12.2 
Address List 
12.2.1 
Sponsor 
AstraZeneca AB 
Västra Mälarehamnen, SE-151 85  
Södertälje, Sweden 
 
12.2.2 
Contract Research Organization 
Medpace, Inc. 
5375 Medpace Way 
Cincinnati, OH 45227 
United States 
12.2.3 
Serious Adverse Event Reporting 
Medpace Clinical Safety 
Medpace SAE hotline  United States: 
12.2.4 
Biological Specimens 
Central laboratory 
Medpace Reference Laboratories, LLC. 
5365 Medpace Way 
Cincinnati, OH 45227 
United States 
Pharmacokinetic laboratory 
Medpace Bioanalytical Laboratories, LLC. 
5365 Medpace Way 

AstraZeneca  
Clinical Study Protocol D6971C00001
Confidential & Proprietary 
Page 57 of 66 
Version 2.0, 31 March 2023 
Cincinnati, OH 45227 
United States 
12.2.5 
Central Pharmacy 
GoGoMeds 
Specialty Medical Drugstore, LLC. 
525 Alexandria Pike, Suite 100 
Southgate, KY 41071 
United States 
12.2.6 
Central Depot 
Clinigen Clinical Supplies Management Inc. 
300 Technology Drive 
Malvern, PA 19355 
United States 
 
Clinigen Clinical Supplies Management Inc. 
342 42nd Street South 
Fargo, ND 58103 
United States 

AstraZeneca  
Clinical Study Protocol D6971C00001
Confidential & Proprietary 
Page 58 of 66 
Version 2.0, 31 March 2023 
13 
REFERENCES 
1. 
Duprez DA. Aldosterone and the vasculature: mechanisms mediating resistant 
hypertension. J Clin Hypertens (Greenwich). 2007;9(1 Suppl 1):13-18. 
2. 
Funder JW. Reconsidering the roles of the mineralocorticoid receptor. Hypertension. 
2009;53(2):286-290. 
3. 
Sato A, Saruta T. Aldosterone-induced organ damage: plasma aldosterone level and 
inappropriate salt status. Hypertens Res. 2004;27(5):303-310. 
4. 
Weldon SM, Brown NF. Inhibitors of aldosterone synthase. Vitam Horm. 
2019;109:211-239. 
5. 
Oelkers W. Adrenal insufficiency. N Engl J Med. 1996;335(16):1206-1212. 
6. 
Wagner RL, White PF, Kan PB, et al. Inhibition of adrenal steroidogenesis by the 
anesthetic etomidate. N Engl J Med. 1984;310(22):1415-1421. 
7. 
Wagner RL, White PF. Etomidate inhibits adrenocortical function in surgical patients. 
Anesthesiology. 1984;61(6):647-651. 
8. 
Calhoun DA, White WB, Krum H, et al. Effects of a novel aldosterone synthase inhibitor 
for treatment of primary hypertension: results of a randomized, double-blind, placebo- and 
active-controlled phase 2 trial. Circulation. 2011;124(18):1945-1955. 
9. 
Karns AD, Bral JM, Hartman D, et al. Study of aldosterone synthase inhibition as an add-on 
therapy in resistant hypertension. J Clin Hypertens (Greenwich). 2013;15(3):186-192. 
 

AstraZeneca Pharma, Inc.
Clinical Study Protocol D6971C00001 
Confidential & Proprietary 
Page 59 of 66 
Version 2.0, 31 March 2023 
APPENDIX A:  SCHEDULE OF PROCEDURES 
Table 1. Schedule of Procedures  Open-Label Extension 
Visita
Treatment Period 
Follow-Up 
1b 
(Visits 6 or 9 of 
Study CIN-107-124) 
2 
3 
4 
5 
6 
7 (EOT)/ET 
8 
Week
1 
2 
6 
12 
24 
38 
52 
56 
Day
( Visit Window)
1 
(-) 
7 
(±2 days) 
42 
(±7 days) 
84 
(±7 days) 
168 
(±14 days) 
266 
(±14 days) 
364 
(±14 days) 
392 
(±14 days) 
Informed consentc 
X 
 
 
 
 
 
 
 
Inclusion/exclusion criteria 
Xd 
 
 
 
 
 
 
 
Adverse events 
----------------------------------------------------------X----------------------------------------------------------
 
Prior/concomitant medications 
----------------------------------------------------------X----------------------------------------------------------
 
Weight, height, and BMIe 
Xd 
X 
X 
X 
X 
X 
X 
 
Upper arm circumference 
Xd 
 
 
 
 
 
 
 
Vital signs, including seated BPf 
X 
X 
X 
X 
X 
X 
X 
X 
Standing BP and heart rateg 
X 
X 
X 
X 
X 
X 
X 
 
Complete physical examinationh 
X 
 
 
 
 
 
 
 
Limited physical examinationi 
 
X 
X 
X 
X 
X 
X 
 
12-lead ECGj 
X 
 
 
 
 
 
X 
 
Urinalysis 
X 
X 
X 
X 
X 
X 
X 
 
Standard safety chemistry panel, 
hematology, coagulation 
X 
X 
X 
X 
X 
X 
X 
X 
Pregnancy testk 
X 
 
 
 
 
 
X 
 
PD blood samplingl 
 
X 
X 
X 
X 
X  
X 
 
PK blood samplingm 
 
 
 
 
 
X 
X 
 
Dispense/collect study drugn 
Xd 
----------------------------------------X-----------------------------------------
 
 
Administer study drugo 
Xd 
X 
X 
X 
X 
X 
X 
 
Assess treatment adherencep 
 
X 
X 
X 
X 
X 
X 
 
Adherence counselingq 
Xd 
X 
X 
X 
X 
X 
X 
 
Provide instructions for next visitr 
Xd 
X 
X 
X 
X 
X 
X 
 
Provide materials for next 24-hour 
urine collections 
 
 
 
 
 
X 
 
 
Obtain sample from 24-hour urine 
collectiont 
 
 
 
 
 
 
X 
 

AstraZeneca Pharma, Inc.
Clinical Study Protocol D6971C00001 
Confidential & Proprietary 
Page 60 of 66 
Version 2.0, 31 March 2023 
a. 
All clinical site visits should occur between 6:00 a.m. and 11:00 a.m. Unscheduled visits may be scheduled at any time during the study period based on the 
discretion. 
b.
The EOT assessments at the end of Part 1 or Part 2 of Study CIN-107-124 will serve as the Day 1 pre-dose assessments for those enrolling in Study CIN-107-130. 
c. 
Written informed consent must be obtained before any Protocol-specific procedures are performed. 
d.
Procedure to be completed pre-dose on Day 1 of Study CIN-107-130. 
e. 
Height will be collected at enrollment (Visit 1) only and will be used to calculate BMI at subsequent visits. See Section 8.12 for details on body measurements.  
f. 
The patient should be seated for at least 5 minutes in the examination room before measurement of vital signs and BP. Vital signs and BP will be measured pre-dose using the 
standardized procedures listed in Section 8.9. 
g.
Once the seated BP has been determined, the patient will be asked to stand, and after 60 seconds, a single standing BP and heart rate (orthostatic vital signs) measurement will 
be obtained. 
h.
A complete physical examination will consist of general appearance, skin, head, eyes, ears, mouth, oropharynx, neck, heart, lungs, abdomen, extremities, and neuromuscular 
system. 
i.
A limited physical examination will consist of a minimum of general appearance, skin, heart, lungs, and abdomen. 
j.
Perform 12-lead ECG after the patient has been resting in the supine position for at least 10 minutes and after measuring vital signs and BP. 
k.
For female patients of childbearing potential (ie, ovulating, pre-menopausal, and not surgically sterile), perform serum pregnancy tests at enrollment (Visit 1) and 
EOT (Visit 7)/ET.  
l.
Pre-dose blood samples for PD analysis will be collected at specified visits. See Section 7.2.1 for details of blood sample collection for PD analysis. 
m. Pre-dose blood samples for PK analysis will be collected within approximately 15 minutes prior to dosing. See Section 7.3 for details of blood sample collection for PK analysis. 
n.
Study drug dispensation may occur at any time starting at enrollment (Visit 1) and before EOT (Visit 7). A Study Reference Manual with details of study drug dispensation and 
collection of unused study drug will be provided to clinical sites. 
o.
On clinical site visit days, patients will self-administer the morning dose of any other concomitant medications (if applicable) at home. CIN-107 should be withheld as it will 
be self-administered at the clinical site and witnessed by site staff, after completion of pre-dose evaluations and laboratory sampling. Between clinical site visits, patients will 
continue to self-administer CIN-107 QD by mouth at approximately the same time each morning. 
p.
Site staff will calculate treatment adherence based on pill counts. 
q.
Site staff will counsel patients about the importance of adhering to the following: study drug, background antihypertensive regimen (if applicable). 
r. 
Instruct patients to take their scheduled morning doses of the antihypertensive medication(s) at home and to hold their dose of CIN-107 on the morning of their next visit. 
Instruct patients to bring their antihypertensive medication(s) and study drug to all clinical site visits for pill counts. Patients should not exercise, smoke, or consume caffeinated 
beverages or food for at least 2 hours prior to each clinical site visit. 
s.
Clinical sites will provide patients with a 24-hour urine collection kit at Visit 6. Patients will be instructed to start the collection up to 3 days prior to Visit 7, refrigerate the 
collected sample, and bring the entire sample to the clinical site at Visit 7. A 24-hour urine collection will commence after the first morning void on the first day and will include 
the first morning void on the second day for a total duration of 24 (±2) hours. Patients must be instructed to keep the sample refrigerated at all times except during their transit 
to the clinical site. 
t.
A 24-hour urine collection may be repeated if the Investigator suspects that the sampling is insufficient and the patient is within the visit window. Clinical sites will aliquot 
urine into a transfer tube and send it to the Central Laboratory. 
BMI = body mass index; BP = blood pressure; ECG = electrocardiogram; EOT = End of Treatment; ET = Early Termination; PD = pharmacodynamic(s); PK = pharmacokinetic(s); 
QD = once daily.

AstraZeneca 
Clinical Study Protocol D6971C00001
Confidential & Proprietary 
Page 61 of 66 
Version 2.0, 31 March 2023 
APPENDIX B:  CLINICAL LABORATORY ANALYTES 
Standard Safety Chemistry Panel 
Alanine aminotransferase 
Albumin 
Alkaline phosphatase 
Amylase 
Aspartate aminotransferase 
Bicarbonate 
Blood urea nitrogen 
Calcium 
Chloride 
Creatine kinase 
Creatinine 
Estimated glomerular filtration rate [1] 
Gamma-glutamyl transferase 
Glucose 
Inorganic phosphorus 
Lactate dehydrogenase 
Lipase 
Potassium 
Sodium 
Total bilirubin 
Total protein 
Uric acid 
1. 
Calculated using the Chronic Kidney Disease Epidemiology Collaboration equation: 
Estimated glomerular filtration rate (mL/min/1.73 m2) = 141 × 
 × 
-1.209 × 0.993Age × 1.018 (if 
female) × 
in 
-0.329 (females) or -0.411 (males); and max indicates the maximum of 
 
Source: Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate [published 
correction appears in Ann Intern Med. 2011;155(6):408]. Ann Intern Med. 2009;150(9):604-612. 
 
Endocrinology 
-human chorionic gonadotropin [1] 
 
1. 
Serum pregnancy tests will be performed only for female patients of childbearing potential (ie, ovulating, 
pre-menopausal, and not surgically sterile). 
 
Hematology 
Hematocrit 
Hemoglobin 
Platelets 
Red blood cell count 
White blood cell count and differential [1] 
 
1. 
Manual microscopic review will be performed only if white blood cell count and/or differential values are out of 
reference range. 
 
Urinalysis 
Bilirubin 
Blood 
Glucose 
Ketones 
Leukocyte esterase 
Microscopy [1] 
Nitrite 
pH 
Protein 
Specific gravity 
Urobilinogen 
 
1. 
Microscopy will be performed only as needed based on positive dipstick test results. 
 

AstraZeneca 
Clinical Study Protocol D6971C00001
Confidential & Proprietary 
Page 62 of 66 
Version 2.0, 31 March 2023 
Coagulation 
Activated partial thromboplastin time 
International normalized ratio 
Prothrombin time 
 
 
Pharmacodynamic Analytes 
Aldosterone and its precursors [1] 
(18-hydroxycorticosterone, corticosterone, 
and 11-deoxycorticosterone) 
Cortisol [2] and its precursor 
11-deoxycortisol 
NT-proB-type natriuretic peptide 
Plasma renin activity [1] 
1. 
Analyte will be used to calculate aldosterone/plasma renin activity ratio. 
2. 
Total cortisol will be measured. Measurement of free cortisol will be performed if changes are noted in total cortisol. 
 
Pharmacokinetic Analytes 
CIN-107 
Any measured metabolite(s) of CIN-107 
 
Twenty-Four-Hour Urine Collection Analytes 
Albumin 
Aldosterone 
Creatinine 
Potassium 
Protein 
Renin 
Sodium 
 
 

AstraZeneca 
Clinical Study Protocol D6971C00001
Confidential & Proprietary 
Page 63 of 66 
Version 2.0, 31 March 2023 
APPENDIX C:  ELECTROCARDIOGRAM ALERT CRITERIA 
GUIDANCE 
Investigators should contact the Sponsor or designee if any clinically meaningful changes from 
baseline (Visit 1) electrocardiograms, including but not limited to those listed below, are noted 
upon review: 
 Heart rate-
QTcF) 450 msec (male); 
 QTcF 470 msec (female); 
 A >60 msec increase in QTcF from baseline; 
 A 6% increase in QTcF from baseline; or 
 New onset findings including, but not limited to, the following: 
o Second degree atrioventricular (AV) block (Mobitz II); 
o Third degree AV block (complete heart block); 
o Acute myocardial infarction; 
o New left bundle branch block; 
o Severe bradycardia (ventricular rate 40 beats per minute [bpm]); 
o Supraventricular tachycardia (ventricular rate 150 bpm); 
o Torsades de pointes; 
o Ventricular tachycardia ( 3 beats regardless of rate); 
o Ventricular fibrillation; or 
o Atrial fibrillation/atrial flutter (ventricular rate 150 bpm). 
 
 

AstraZeneca 
Clinical Study Protocol D6971C00001
Confidential & Proprietary 
Page 64 of 66 
Version 2.0, 31 March 2023 
APPENDIX D:  EXAMPLES OF EXCLUDED MEDICATIONS 
Each concomitant medication should be assessed individually for its potential for a drug-drug 
interaction. For examples of clinical inhibitors and substrates of the listed transporters and clinical 
inducers for cytochrome P450-mediated metabolisms, see the online reference at 
https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-
table-substrates-inhibitors-and-inducers. 
An extract of this website on 24 June 2021 is reflected in Table 2. 
Table 2. 
Examples of Excluded Medications 
Group 
Examples 
Strong CYP3A inducers [1] 
Apalutamide, carbamazepine [2], enzalutamide [3], mitotane, 
phenytoin [4], 
 
1. 
Examples of clinical inducers for P450-mediated metabolisms (for concomitant use clinical DDI studies and/or drug 
labeling) (12/03/2019). 
Note: Strong, moderate, and weak inducers are drugs that decrease the AUC of sensitive index substrates of a given 
metabolic pathway by 80%, 50% to <80%, and 20% to <50%, respectively. 
2. 
Strong inducer of CYP2B6, CYP3A, and weak inducer of CYP2C9. 
3. 
Strong inducer of CYP3A and moderate inducer of CYP2C9, and CYP2C19. 
4. 
Strong inducer of CYP2C19, CYP3A, and moderate inducer of CYP1A2, CYP2B6, CYP2C8, and CYP2C9. 
5. 
Strong inducer of CYP3A and moderate inducer of CYP1A2, and CYP2C19. 
6. 
 
AUC = area under the concentration-time curve; CYP = cytochrome P450; DDI = drug-drug interaction. 
 
 
 

AstraZeneca 
Clinical Study Protocol D6971C00001
Confidential & Proprietary 
Page 65 of 66 
Version 2.0, 31 March 2023 
APPENDIX E:  RESCUE MEDICATION GUIDANCE 
The following guidelines should be utilized for selection of rescue medication: 
 If a hypertensive emergency appears imminent, refer the patient to seek urgent care in a clinic 
or hospital. 
 Rescue medication use is permitted and recommended if the following blood pressure (BP) 
measurements are recorded in office: 
o Systolic BP (SBP) shows an acute and sustained increase of 30 mmHg (or greater) from 
baseline (Visit 1) measurement; and/or 
o SBP is 170 mmHg; and/or  
o Diastolic blood pressure is 105 mmHg. 
 BP must be determined prior to initiation of any rescue medication. Additional study 
procedures for safety, tolerability, and effectiveness endpoints assessments will be performed 
as outlined in Appendix A. 
 Investigators should use their best clinical judgment when determining the need for rescue 
medications.  
o The following classes of antihypertensive agents may be used during the study: 
 Vasodilators; 
 Calcium channel blockers; 
 Angiotensin-converting enzyme inhibitors; 
 Angiotensin II receptor blockers; 
 Beta blockers;  
 Diuretics (Note: Use of potassium-sparing diuretics and mineralocorticoid receptor 
antagonists are not allowed); and 
 Alpha blockers.  
o The following class of antihypertensive agents should not be used during the study: 
 Potassium-sparing diuretics; and 
 Mineralocorticoid receptor antagonists. 
 Investigators are encouraged to discuss selection of rescue medications with the study Medical 
Monitors. 
 Rescue medications may be continued until end of the study or discontinued at the 
 
 Down-titration of antihypertensive medication(s) is allowed as detailed in Appendix F.  

AstraZeneca 
Clinical Study Protocol D6971C00001
Confidential & Proprietary 
Page 66 of 66 
Version 2.0, 31 March 2023 
APPENDIX F:  DOWN-TITRATION OF ANTIHYPERTENSIVE 
MEDICATION(S) 
Down-titration of antihypertensive medication(s) is recommended for management of persistent 
or symptomatic hypotension in study patients. The following recommendations are provided as 
guidance to the Investigator: 
 The guiding principle for medical decision making with regard to blood pressure (BP) 
management in this study is to try to maintain patients on the highest dose of CIN-107 that is 
safe and medically reasonable. Study drug should be continued unless the Investigator feels it 
is necessary to stop for the safety of the patient. 
 To manage persistent or symptomatic hypotension in a step-wise fashion, the following are 
recommended to Investigators: 
o First, any rescue medication (see Appendix E) that may have been started should be 
reduced or discontinued; 
o Then, the use of the single background antihypertensive (non-CIN-107) agent should be 
reduced or discontinued, if medically sound; 
o If the symptoms continue, the dose strength of CIN-107 may be down-titrated from 2 mg 
to 1 mg;  
o If the systolic BP (SBP) remains 100 mmHg on 3 consecutive days or if symptoms persist, 
the CIN-107 dose may be further down titrated to 0.5 mg; 
o CIN-107 may be temporarily discontinued if the SBP remains <90 mmHg for 
3 consecutive days or if symptoms persist; and 
o Study drug dosing may be resumed or up-titrated after reassessments.